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1.1 Wallerian degeneration and slow Wallerian degeneration Mouse, C57BL/WldS 
Wallerian degeneration is the degeneration of the distal stump of an injured axon (Waller, 
1850). It normally occurs over a time course of around 24-48 hr of a lesion, such as 
mechanical (transection, crush, blunt trauma), chemical toxic (acrylamide), or metabolic 
(ischemia) injuries. It includes disintegration of the axonal cytoskeleton and 
fragmentation of the axon, followed by breakdown of myelin sheath, macrophage 
infiltration and Schwann cell proliferation (Figure 1.1). It is not known how Wallerian 
degeneration is initiated, but the mechanism clearly involves an active and regulated 
program of self-destruction and is distinct from neuronal cell body apoptotic 
degeneration: in WldS, neurites of sympathetic ganglia undergo slow Wallerian 
degeneration after deprivation of their physiological trophic factor (nerve growth factor), 
however the neuronal soma degenerates normally as wild type (Deckwerth & Johnson, 
1994); overexpression of Bcl-2, a anti-apoptosis protein, prevents motoneuron cell body 
loss but not axonal degeneration in a mouse model of motor neuron disease (progressive 
motor neuronopathy, pmn/pmn)(Sagot et al, 1995); Wallerian degeneration and NGF-
withdrawal-induced axonal degeneration do not activate classical caspase cascade 
happening in cell body’s apoptosis, and caspase inhibitors do not block axonal 
degeneration (Finn et al, 2000).   
The slow Wallerian degeneration mouse, C57BL/Wlds, carries a dominant mutation that 
delays Wallerian degeneration in the distal stump of an injured axon. It is a spontaneous 
mutant that was revealed by experiments to investigate the role of macrophages in 
peripheral-nerve repair (Lunn et al, 1989). Transected axons from the PNS (such as 
sciatic nerve and tibial nerve) or CNS (such as optic nerve) of the Wlds retain the ability 
to transmit a compound action potential for up to 3 weeks (Lunn et al 1989; Ludwin and 
Bisby, 1992; Watson et al, 1993), and continue the anterograde and retrograde transport 
of proteins for a similar length of time (Smith & Bisby, 1993; Glass & Griffin, 1994). In 
fact, all PNS and CNS neuronal subtypes studied show delayed Wallerian degeneration, 
including motor and sensory neurons, sympathetic neurons, and retinal gangalion cells 
(Lunn et al, 1989; Perry et al, 1991; Deckwerth & Johnson, 1994). The neuroprotective 
phenotype is dominant and intrinsic to the axon (Perry et al, 1990; Glass et al, 1993; 
Deckwerth & Johnson, 1994; Buckmaster et al, 1995). The existence of a putative 
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regulatory molecule in axons suggests that Wallerian degeneration is not a passive 
process, as previously thought, but an active one that removes damaged axons 
(Buckmaster et al, 1995). Surprisingly, such mutant is developmentally normal, with 
unaltered axon numbers or synapse elimination (Perry et al 1990; Parson et al, 1997). 
Thus WldS offers an attractive route to therapy that may have few side effects. 
Axonal degeneration, including Wallerian degeneration, is considered to occur through 
the activation of a local self-destruct program, which is distinct from apoptosis 
(programmed cell death) (Raff and Finn, 2002). So far, apoptosis is considered as 
responsible for neuronal cell death in the developing nervous system and probably in 
certain pathological states such as ischemia and neurodegenerative diseases. It relies on a 
cascade of enzymes. Most of these are caspases, enzymes that are expressed as inactive 
precursors (procaspases) and are activated by being cleaved at specific peptide bonds. 
Likewise, activated caspases in turn activate procaspases at the next point in the enzyme 
chain by cleaving them at specific bonds. Caspases early in the cascade are activated after 
a death-inducing signal propagates to the mitochondria, which release several proteins 
including cytochrome c. Cytochrome c, the adaptor protein Apaf-1, the enzyme precursor 
procaspase-9 and dATP form the ‘apoptosome’ death complex. Procaspase-9 is cleaved 
to form the active enzyme, caspase-9, which activates caspases 3, 6 and 7 in the same 
way. These enzymes cleave several intracellular substrates, such as ICAD (resulting 
eventually in DNA fragmentation) and other cell-death regulators, ensuring the death of 
the cell. Several different proteins acting as ‘roadblocks’ prevent unwanted cell death by 
controlling the cytochrome c release or the ability of caspases to bind to linker molecules. 
For example, Bcl-2 proteins regulate the release of proteins from mitochondria; inhibitor-
of-apoptosis proteins (IAPs) bind procaspases (to prevent them being activated) and 
active caspases (to inhibit their activity).   
Wallerian degeneration was, until recently, considered as a passive mechanism, with 
axons degenerating through loss of the inhibitory influence of neuronal trophic substance 
on the Schwann cell due to the nerve interruption, loss of protein synthesis in the cell 
body or activation of Ca2+-dependent protease (Lubinska, 1977; Schlaepfer and Hasler, 
1979). The picture has changed dramatically with the discovery of the WldS mutant and 
further the identification of the responsible 85 kb triplication region and chimeric gene 
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(Ube4b/Nmnat) within the region (Lunn et al, 1989; Coleman et al, 1998; Conforti et al, 
2000; Mack et al, 2001). Although the molecular mechanism of Wallerian degeneration 
is still not clear, WldS offers an attractive route into this problem because identifying the 
gene should lead to regulators of Wallerian degenration. In addition to that, the Wlds 
mutant also gives a great potential to investigate its role in protecting or alleviating 
neurological diseases, such as myelin-related neuropathy, multiple sclerosis and 
amyotrophic lateral sclerosis (Coleman and Perry, 2002).   
1.2 Molecular genetics of WldS 
The WldS mutation has been mapped to distal mouse chromosome 4 (Lyon et al, 1993), 
and a tandem triplication of an 85-kb genomic region has been identified within a genetic 
candidate interval (Coleman et al, 1998). Exons of three genes were identified within the 
85-kb tandem triplication unit (Conforti et al, 2000) (Figure 1.2). Ubiquitination factor 
E4B (Ube4b) and nicotinamide mononucleotide adenylytransferase (Nmnat), span the 
distal and proximal boundaries of the repeat unit, respectively. They have the same 
chromosomal orientation and form a chimeric gene when brought together at the 
boundaries between adjacent repeat units in WldS. The chimeric mRNA is abundantly 
expressed in the nervous system and consists of the N-terminal 210 coding nucleotides of 
Ube4b, the entire 855 coding nucleotides of Nmnat, and 54 nucleotides formed at the 
junction (Figure 1.2 and Figure 1.3b). The third gene altered by the triplication, Rbp7, is a 
novel member of the cellular retinoid-binding protein family. Although the function of 
Rbp7 is unknown, cellular retinoid-binding proteins, most of which are belonging to the 
fatty acid-binding protein/cellular retinol-binding protein family, have been well 
characterized in controlling the concentration of free retinoids and in directing protein-
bound retinoids to key enzymes responsible for their metabolism. For example, the 
cellular retinol-binding protein, CRBP, has been implicated in retinol uptake, retinol 
esterification, mobilization of retinyl esters, and the initial oxidation of retinol to 
retinaldehyde. It is also conceivable that an alternation in retinoid metabolism could 
influence axonal survival given that retinoic acid can induce neuronal differentiation, 
increase nNOS (neuronal nitric oxide synthase) levels in vitro, and participate in the 
cholinergic potentiation of synaptic activity (Sidell et al, 1983; Ando et al, 1996; 
Personett et al, 2000).  However, while Rbp7 is highly expressed in white adipose tissue 
 5
and mammary gland, it is undetectable on northern blots of WldS brain. This suggests that 
it is unlikely to play a role in delaying Wallerian degeneration of axons, but does not rule 
it out.   
1.3 Triplication and its genomic stability 
Germ-line triplication is a rare event. However, Reddy and Logan (2000) found a 
triplication with an inverted middle repeat in 13q22q33 in a new born boy with multiple 
complications including meconium aspiration syndrome (Reddy and Logan, 2000) and 
also found triplications in 15q11q13 and 2q112q21. Thus they suggest that 
intrachromosomal triplication may be more prevalent than previously assumed and can 
sometimes be mistaken for duplications. Some rare triplications have also found within 
the α globin gene cluster (Villegas et al, 1995). An 85-kb tandem triplication has been 
identified in the WldS mouse (Coleman et al, 1998). There are very few reports of tandem 
triplications in a vertebrate. Perhaps the best-studied tandem triplication is that of the 
Drosophila double Bar mutant, which was shown to arise following a recombination 
event of the original Bar duplication, using polytene banding patterns long before the 
advent of molecular genetics (Sturtevant et al, 1925; Muller et al, 1936; Bridges et al, 
1936). Such triplication is mediated by homologous, but unequal, crossing-over between 
tandem head-to-tail repeated DNA sequences (Jeffreys et al, 1988; Tartof, 1988). 
Very little is known about genomic instability of triplications, although it is clear that 
duplications of similar repeat unit length can be unstable in mammals, for examples the 
70-kb pink-eyed unstable (pun) duplication that frequently reverts to wild type (Gondo et 
al, 1993). Initial experiments in Wlds mice showed that some duplication alleles also 
existed in two out of seven mice analyzed (Coleman et al, 1998). So, like double Bar, the 
tandem triplication in the WldS mouse is very likely to have developed from duplication, 
which, like the mouse pink-eyed unstable (pun) mutation, was unstable. However, unlike 
pink-eyed, WldS contains no genes that are harmful at the increased dosage. 
A study of the genomic instability of the triplication in WldS is important to understand 
the gene dosage that is present in WldS mice and to facilitate the study of the potential 
role of Wld in neuroprotection, such as crossing WldS with mouse model of 
neurodegenerative diseases. 
1.4 The chimeric gene is the WldS gene 
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During the course of the experiments described, it has been confirmed that the 
Ube4b/Nmnat chimeric gene confers the slow Wallerian degeneration phenotype using 
transgenic mice expressing the Ube4b/Nmnat cDNA from an b-actin promoter. The WldS 
phenotype was reproduced fully in one line (line 4836) and partially in three other lines 
(lines 4830, 4858 and 4839) with a phenotype strength determined by transgene 
expression level, thus proving that the chimeric gene is the Wld gene (Mack et al, 2001). 
The protective gene thus confers a dose-dependent block of Wallerian degeneration. 
Expression of Wld needs to reach a threshold level to exert a significant protective effect: 
transected distal axons (69%-73%) survived for two weeks in transgenic line 4836 
homozygotes which has the highest expression level, however the protection was 
considerably weaker with only 7% surviving in line 4836 hemizygotes. In addition, motor 
nerve conduction, synaptic transmission, vesicle recycling and motor nerve terminal 
morphology were also preserved in a dose-dependent manner. 
Ube4b/Nmnat chimeric gene encodes a 43-kDa in-frame fusion protein consisting of the 
N-terminal 70 amino acid of Ube4b, the C-terminal 285 amino acids of Nmnat, and 18 
amino acids formed at the junction (Figure 1.3).  
The protective mechanism is unknown. Using an antibody described in section 6.2.1, the 
WldS protein was detected predominantly in the nucleus of WldS and transgenic neurons, 
indicating an indirect protective mechanism. Although we could not rule out that a 
possible extremely low and undetectable level of WldS protein might exist in axons, it is 
unlikely that the predominantly nuclear localization of WldS does not play a role in 
protecting axons. The yeast homologue (Ufd2) of Ube4b is required to multi-ubiquitinate 
some substrate proteins (Koegl et al, 1999) and a direct link between ubiquitination and 
axon degeneration comes from the Uch-l1 mutation in gracile axonal dystrophy (Saigoh 
et al, 1999 and see section 1.6). However, the WldS protein contains only 70 of 1,173 
amino acids from Ube4b, and these are absent from the yeast homologue Ufd2. So far 
ubiquitin-protein ligases (E3s) had been classified into several established families 
including HECT, RING-finger families and U-box proteins (Hershko and Ciechanover, 
1998; Joazeiro and Weissman, 2000; Hatakeyama and Nakayama, 2003). HECT domain 
E3 family was first characterized by its representative member, the E6 associated protein 
(E6-AP). The U-box is a domain of approximately 70 amino acids that is present from 
 7
yeast to humans. The prototype U-box is present in the C-terminal region of yeast Ufd2, 
an ubiquitin chain assembly factor (E4), however absent in the Ube4b-derived N-terminal 
70 amino acids of chimeric protein in WldS. They are therefore unlikely to confer multi-
ubiquitination activity, but may have a related role, such as substrate binding or 
regulation of E3 activity. The protective mechanism may be linked to the nuclear location 
of the WldS protein. Possibilities include sequestering of ubiquitination factors by 
protein-protein interactions and ubiquitination within the nucleus altering transcription 
factor stability or RNA processing, leading to an axon effect mediated by unknown 
proteins. Nmnat is a nuclear protein and has two isoforms of mammalian enzymes 
catalyzing the reaction NMN + ATP ® NAD+ + Ppi (Magni et al, 1999; Raffaelli et al, 
2002), a reaction generally assumed not to be at equilibrium because of the constitutive 
action of pyrophosphatases. We confirmed that WldS protein has Nmnat enzyme activity 
and found a fourfold increase of Nmnat activity in WldS brain homogenates compared to 
C57BL/6J, but the total content of NAD+ was not significantly altered (see section 6.2.1). 
Thus, the increase in Nmnat activity in WldS should increase NAD+ synthesis, and the 
maintenance of normal steady-state levels suggests that the putative additional NAD+ is 
metabolized. The product of a compensatory reaction could itself be involved in axon 
protection. For example, poly-ADP ribosylation uses NAD+, influencing protein activity 
and cellular NAD+ and ATP content, especially in response to stress (Smith, 2001; Ha 
and Snyder, 1999). Mild activation of PARP-1 without NAD+ depletion can be 
neuroprotective (Nagayama et al, 2000). Another metabolite, NADH, is a coenzyme for 
nitric oxide synthase, an enzyme linked to axon damage, and synthesis of the signaling 
molecule cyclic ADP ribose from NAD+ regulates calcium release from intracellular 
stores, potentially influencing calcium activated proteases in Wallerian degeneration 
(Smith et al, 2001; Di Lisa & Ziegler, 2001).  
1.5 Slow Wallerian degeneration Mouse, C57BL/WldS and human disease 
The morphological features of Wallerian degeneration – the granular disintegration and 
beading of an axon distal to a site of injury – can be triggered by neurotoxins, and by 
defects in myelin, axonal transport or oxygen delivery (Waller, 1850; Cliffer et al, 1998; 
Frei et al, 1999; Probst et al, 2000; Oosthuyse et al, 2001; Garbern et al, 2002). 
Wallerian degeneration per se is a model for the mechanism of axon death in many 
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diseases of the central and peripheral nervous system such as multiple sclerosis, 
amyotrophic lateral sclerosis and peripheral neuropathy (Waller, 1850; Dal & Gurney, 
1995; Fujimura, 1991). In addition, other diseases, such as dying-back type neuropathies, 
are traditionally considered distinct from Wallerian degeneration, although there is no 
evidence that their mechanisms are unrelated (Saigoh et al, 1999; Frei et al, 1999; 
Cifuentes-Diaz et al, 2002). Recent data shows that Wallerian degeneration and dying-
back axon degeneration might share some mechanism in common (Wang et al, 2002); 
and this could be extended to other neurodegenerative disorders, see section 3.2.2. Since 
axon loss is a major cause of symptoms, even in disorders where the primary defect lies 
elsewhere, identification of the WldS gene facilitates studies to determine whether it 
protects axons in clinically relevant situations. The WldS mutation is already known to 
protect neuronal processes on primary sensory neuronal culture in vitro from the toxic 
effects of vincristine, suggesting a possible role in combating neurodegeneration induced 
by chemotherapy (Wang et al, 2001). Studies in which I collaborated indicate that distal 
axon loss in myelin protein zero deficient mutants (P0) is partially rescued by WldS 
(Samsam et al, 2003 and see section 3.2.2), and that WldS protects axon loss in Pmn, a 
mouse model of motor neuron disease (Ferri et al, 2003 and see section 3.2.2). In 
addition to that, WldS should shed light on the roles of axon loss in multiple sclerosis 
(MS), amyotrophic lateral sclerosis (ALS), axonal transport defects (such as Charcot-
Marie-Tooth disease type 2A, peripheral neuropathy) (Zhao et al, 2001; Cliffer et al, 
1998), and acute disorders (such as brain trauma and stroke) (Sherriff et al, 1994; 
Graham et al 2000; Stys, 1998).  WldS-derived knowledge might even lead towards a 
therapy for axons in such clinical situations.  Since axon injury has recently emerged as a 
substantial, and perhaps the key component of MS pathology, manipulating the survival 
of axons, such as WldS does, could lead more axons to survive a period of demyelination 
and then recover, thus arresting the decline from a relapsing-remitting disease to a 
progressive one (Narayanan et al, 1997; Sherriff et al, 1994). As in MS, there is 
considerable axonal loss in human ALS and in animal models of ALS and spinal 
muscular atrophy (Oosthuyse et al, 2001; Cifuentes-Diaz et al, 2002; Dal & Gurney, 
1994). It has been reported, that prevention of axonal loss in pmn does improve the 
phenotype (Sagot et al, 2000; Ferri et al, 2003). Delaying Wallerian degeneration might 
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well preserve axons, although could not unblock axonal transport, while another 
treatment removes the blockage. In brain trauma, axon transection is not necessarily 
instantaneous upon injury and can occur hours later, giving a window of opportunity in 
which to save axons (Jafari et al, 1997). In stroke, there is large component of damage in 
white matter, thus minimizing the loss of the axons could offer new therapeutic 
opportunities (Dewar et al, 1999).     
Those observations above have many important implications: 1) a pathway related to 
Wallerian degeneration occurs in disease-related processes. Thus, understanding the 
Wallerian degeneration mechanism is relevant to non-injury disorders such as dying-back 
neuropathies; 2) WldS is a valuable and unique experimental tool with which to probe the 
contribution of axonal degeneration to numerous neurodegenerative models; 3) such 
studies could lead to the development of novel therapeutic strategies.  
1.6 The gad mouse (gracile axonal dystrophy) 
The gracile axonal dystrophy mouse is an autosomal recessive mutant that shows sensory 
ataxia at an early stage (first detectable at 30 days after birth), followed by motor ataxia 
(detectable about 60 days after birth) (Yamazaki et al, 1988). Pathologically, the mutant 
is characterized by ‘dying-back’ type axonal degeneration in both the central and 
peripheral distal ends of primary sensory neurons and the lower motor neurons and 
formation of spheroid body in the central distal ends of gracile tract (Mukoyama et al, 
1989; Kikuchi et al, 1990; Oda et al, 1992; Miura et al, 1993). Recent pathological 
observations have associated neurodegenerative diseases with progressive accumulation 
of ubiquitinated protein conjugates (Arnold et al, 1998; Alves-Rodrigues et al, 1998).  In 
gad mice, accumulation of amyloid b-protein and ubiquitin-positive deposits occur 
retrogradely along the sensory and motor nervous system (Ichihara et al, 1995; Wu et al, 
1996). The gad mutation is caused by an in-frame deletion including exons 7 and 8 of 
Uchl1, encoding the ubiquitin carboxy-terminal hydrolase (UCH) isozyme (Uch-l1) 
selectively expressed in the nervous system and testis (Day & Thompson, 1987; 
Wilkinson et al, 1989; Day et al, 1990; Kajimoto et al, 1992; Saigoh et al, 1999)(Figure 
1.4). The gad allele encodes a truncated Uch-l1 lacking a segment of 42 amino acids 
containing a catalytic residue (Larsen et al, 1996). Uch-l1 is known to be involved in the 
process of de-ubiquitination and UCHs are thought to hydrolyse bonds between small 
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adducts and ubiquitin to generate free monomeric ubiquitin (Dang et al, 1998; Larsen et 
al, 1998). Recent data also suggests this neuronal-abundant protein (Uchl1) mediates the 
ubiquitin stability and function in neurons (Osaka et al, in press). Thus, UCHs are 
essential in continuing the function of the ubiquitin system, and the defect in Uch-l1 in 
gad mutation appears to affect protein turnover (Saigoh et al, 1999). The gad mouse is 
the first mammalian model of neurodegeneration with a defect in the ubiquitin system. In 
addition to that, dying-back degenerative process is thought to underlie several 
neurodegenerative diseases in human such as motor neuron disease and peripheral 
neuropathy (Schmalbruch et al, 1991, Samsam et al, 2003), and gad mutant is 
characterized by dying-back type degeneration in both sensory and motor nerve fibers, 
thus it could be also expected to provide important information on the pathogenesis of 
some neurodegenerative diseases. 
1.7 Ubiquitin metabolism in neurodegeneration  
The integrity of cellular processes depends upon the proper balance of different proteins. 
In cells, there are two major destruction pathways to regulate such activities involving 
either a collection of proteolytic enzymes within the lysosome or the multicatalytic 
proteolytic core of the proteasome. The majority of proteins that are destined for 
proteasome degradation are marked by the covalent attachment of multiple ubiquitin 
molecules, which provide a recognition signal for the 26S proteasome. Such ubiquitin-
proteasome pathway involves two discrete and successive steps: a specific recognition 
process, employing the ubiquitin conjugation cascade, and secondly, an indiscriminate 
destruction process, mediated by the proteolytic proteasome core. The ubiquitin 
conjugation cascade uses E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating 
enzyme), E3 (ubiquitin ligase) and E4 (ubiquitin elongation factor) to shuttle ubiquitin 
and eventually link ubiquitin to the protein substrates, which then targeted by proteasome 
for degradation (Myung et al, 2001; Koegl et al, 1999).  
Such ubiquitin-proteasome pathway is considered to play a central role in the processing 
of damaged and toxic protein, and thus impairing such a pathway could lead to the 
abnormal accumulation and processing of mutant or damaged intra- and extracellular 
proteins and finally cause neuronal dysfunction and cell death. In a variety of 
neurodegenerative diseases, such ubiquitin-positive protein aggregates or inclusion 
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bodies could be found, for example in the prion protein (PrP) plaques in prion disease, 
amyloid plaques and neurofibrillary tangles in Alzheimer’s disease (AD), Lewy bodies in 
Parkinson’s disease (PD) and nuclear inclusion in the poly-glutamine repeat diseases 
such as Huntington’s disease (HD), spinocerebellar ataxias (SCA) (Hardy and Gwinn-
Hardy, 1998; Alves-Rodringues et al, 1998; Kenward et al, 1994). The mutation of two 
genes (Uch-l1 and Parkin) within the ubiquitin-proteasome pathway in hereditary PD and 
recent proof of a mutation in Usp14 encoding a ubiquitin-specific protease in ataxia mice, 
clearly indicate that ubiquitin-proteasome pathway plays a crucial role in the 
pathogenesis of neurodegenerative diseases (Kitada et al, 1998; Leroy et al, 1998; Wilson 
et al, 2002). A missense mutation (Ile93Met) in ubiquitin carboxy-terminal hydrolase L1 
(UCH-L1) gene was identified in a small German pedigree composed of two affected 
family members (Leroy et al, 1998). Since such mutation causes a partial loss of the 
catalytic activity of this protease, which involves in the release of ubiquitin from the 
degraded end products containing small molecules (amines and thiols) and has a potential 
role in mediating ubiquitin stability in axons (Osaka et al, in press), the mutation could 
impair the overall efficiency of the ubiquitin system leading to aggregation of proteins. 
The deletion of exon7 and exon8 of Uchl1 was found to be the causative gene in the first 
mice model (gad) of neurodegeneration with defect in ubiquitin system as well, and such 
ablation of Uch-l1 expression causes the primary defect in the gracile tract of gad mutant, 
which will be discussed in detail in chapter 5. As described before, E3 ubiquitin-ligase is 
involved in recognizing the substrates and mediating the attachment of polyubiquitin 
chains to the substrates, thus it is an important factor in the regulation and selectivity of 
substrates targeted for degradation. Missense mutations in Parkin were identified in 
familial Parkinson disease and further parkin was found to be a ubquitin-protein ligase E3 
(Kitada et al, 1998; Shimura et al, 2000).  Familial-associated mutations in parkin cause 
impaired binding to E2 and defective E3 ligase activity, which might cause the autosomal 
recessive PD (Shimura et al, 2000; Imai et al, 2000; Zhang et al, 2000). Several potential 
substrates for parkin have recently been identified: CDCrel-1 (potential role in regulating 
synaptic vesicle release in nervous system) (Beites et al, 1999), α-synuclein interacting 
protein synphilin-1 (Chung et al, 2001), Pael-R (parkin-associated endothelin-receptor-
like receptor) (Imai et al, 2000) and α-Sp22 (a glycosylated form of α-
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synuclein)(Shimura et al, 2001). Interestingly, ubiquitinated synphilin-1 is enriched in 
Lewy bodies, the hallmark of PD, and thus suggests that familial-associated mutations in 
parkin involve in the pathogenesis of PD. Recently, a mutation in Usp14, encoding an 
ubiquitin-specific protease was identified as the causative gene for ataxia mice (Wilson et 
al, 2002). The function of Usp14 might be associated with cleaving the mono-ubiquitin 
side chain from substrate, and the removal of such mono-ubiquitin would regulate 
processes such as protein localization and protein activity (Katzmann et al, 2001; Hicke, 
2001; Shih et al, 2000). Although neither ubiquitin-positive protein aggregates nor 
neuronal cell loss is detectable in the central nervous system (CNS) of ataxia mice, there 
are defects in synaptic transmission in both the central and peripheral nervous systems, 
and thus suggest that ubiquitin proteases are important in regulating synaptic activity in 
mammals.  
It is clear that the defects in the components of ubiquitin-proteasome pathway play a 
major role in neurodegenerative diseases, thus a full understanding of such intricate 
system could contribute to understand the pathogenesis of these disorders. 
1.8 XFP (especially YFP-H) mice in studying Wallerian degeneration 
A series of methods have been developed before to image individual neurons: from Golgi 
stain to electron microscopy to anterograde and retrograde labeling methods to 
immunohistochemical labeling protocols to confocal microscopy. The introduction of the 
jellyfish green fluorescent protein (GFP) as a vital stain has rendered several useful 
features: GFP is a protein, so the cells could be rendered fluorescent stably and heritably 
by introduction of a cDNA; the GFP chromophore is derived entirely from the 
polypeptide chain without a need of exogenous cofactors or substrates, thus it can be used 
to view living cells with minimal perturbation; GFP can be fused to other proteins 
without loss of fluorescence, thus it can be directed to specific subcellular compartments; 
GFP can be mutated to generate variants (named as XFP) with altered spectral properties 
and improved translational efficiency, thermostability, and quantum yield. As a result of 
these favorable properties, GFP and its variants have been used to follow molecules and 
cells in a lot species (Chalfie et al, 1994; Chalfie and Kain, 1998; Tsien, 1998; Conn, 
1999) and recently, transgenic mice in which red, green, yellow, or cyan fluorescent 
proteins (together termed XFPs, termed RFP, GFP, YFP and CFP respectively) were 
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selectively expressed in neurons were also generated to image individual neurons (Feng 
et al, 2000)(Figure 1.5). All four XFPs labeled neurons in their entirety, including axons, 
nerve terminals, dendrites, and dendritic spines (XFPs label axons over centimeter-long 
distances and dendrites over millimeter-long distances). Expression of XFP for up to 9 
months has no discernible effect on synaptic structure and that multiple imaging of XFP-
labeled neurons in vivo is not detectably toxic. Although there is a remarkable variability 
in patterns of XFP expression among mice generated from the same construct (under the 
neuron-specific thy1-derived regulatory element), expression is unique and heritable 
among offspring of each transgenic founder, indicating the difference due to integration 
site and/or copy number. 
Since YFP-fluorescence is intense in both live and paraformaldehyde-fixed tissues, 
shows good quality of staining axons and nerve terminal and is commercial available, it 
was chosen as a useful tool to study Wallerian degeneration in following attempts: 1) to 
study how Wallerian degeneration initiates and progresses in the axotomised axons. 
Although Wallerian degeneration was described as a process starting from proximal to 
distal at the transection site with fragmentation of axons, the evidence is indirect; 
introducing YFP into WldS mice should give us a clear picture of it; 2) to study synaptic 
changes in WldS mice. Since XFP could label neurons in their entirety including synapses, 
CFP-expressing mice were crossed with WldS mice to study the undergoing mechanism 
of synapse withdrawal and degeneration (Gillingwater et al, 2002); 3) to study synaptic 
and axonal change in mice model of neurological disorders with WldS. Crossing YFP-H 
mice with gad/WldS mice could give us the information of the difference in the nerve 
terminal of gad with WldS or without WldS and thus give us a better picture to understand 
the potential rescue-function of WldS in neurodegenerative disorders (see 5.2.1 and 5.2.6); 
4) to facilitate the mechanism study of Wallerian degneration. Crossing YFP with 
transgenic mice with the expression of N-terminal of 70 amino acid of the chimeric gene 
with NLS or NES could make it easy to visualize the preservation of the axon (see 
section 6.2.2 in detail). 
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Figure 1.1 A schematic diagram shows undergoing Wallerian degeneration: 
disintegration of axonal cytoskeleton and fragmentation of the axon, followed by 
breakdown of the myelin sheath, macrophage infiltration and Schwann cell proliferation. 
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Figure 1.1 Schematic diagram of Wallerian degeneration. 
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Figure 1.2 Location of exons within the 85-kb WldS triplication repeat unit. In WldS, three 
adjacent repeat units are shown to indicate (i) how N-terminal of Ube4b and Nmnat are 
brought together to form a chimeric gene (ii) that normal copies of Ube4b and Nmnat 
exist still at either end of the repeat array (the complete genes are not shown), and (iii) 
how Rbp7 is present at three time the normal copy number. 
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Figure 1.2 Location of exons within the 85-kb WldS triplication repeat unit. 
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Figure 1.3a WldS express novel and wild type proteins: (i) a 43-kDa WldS-specific 
chimeric protein; (ii) Ube4b and Nmnat which express both in wild type C57BL/6J and 
C57BL/WldS. 
 
 
 
 
 
 
Figure 1.3b Sequence of the chimeric cDNA and the predicted coding sequence. The 
vertical arrow indicates the junction between Ube4b and Nmnat (starting from 71aa and 
ending at 88aa), and the amino acid shown in bold are those used to make peptides for 
generation of polyclonal antisera 183 (Ile-325 to Lys-339) and 185 (Thr-64 to His-79) 
(see section 3.2.1 and section 6.2.1). 
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Figure 1.3a WldS express novel and wild type proteins. 
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Figure 1.3b Sequence of the chimeric cDNA and the predicted coding sequence.   
ATGGAGGAGCTGAGCGCTGACGAGATTCGACGGAGGCGCCTGGCACGACTTGCTGGTGGA         
MetGluGluLeuSerAlaAspGluIleArgArgArgArgLeuAlaArgLeuAlaGlyGly 
  
CAGACCTCCCAGCCGACCACCCCGCTTACATCTCCCCAGAGGGAGAACCCTCCGGGACCT 
GlnThrSerGlnProThrThrProLeuThrSerProGlnArgGluAsnProProGlyPro 
 
CCAATAGCTGCATCAGCCCCAGGCCCCTCCCAGAGTCTTGGTCTCAATGTCCACAACATG 
ProIleAlaAlaSerAlaProGlyProSerGlnSerLeuGlyLeuAsnValHisAsnMet 
  
ACCCCAGCTACCTCCCCCATAGGTGCAGCAGACAACATCGCTGTCAGAGGGTTGCATGTA 
ThrProAlaThrSerProIleGlyAlaAlaAspAsnIleAlaValArgGlyLeuHisVal 
  
GGTCAACACCACCAACTTCTCCCCATGGACTCATCCAAGAAGACAGAGGTGGTTCTCCTG 
GlyGlnHisHisGlnLeuLeuProMetAspSerSerLysLysThrGluValValLeuLeu 
 
GCCTGTGGCTCTTTTAACCCCATCACCAACATGCACCTCAGGCTGTTCGAGCTGGCCAAG  
AlaCysGlySerPheAsnProIleThrAsnMetHisLeuArgLeuPheGluLeuAlaLys 
  
GACTATATGCATGCTACAGGAAAATACAGTGTTATCAAAGGCATTATCTCACCGGTCGGT 
AspTyrMetHisAlaThrGlyLysTyrSerValIleLysGlyIleIleSerProValGly 
  
GATGCGTACAAGAAGAAAGGGCTCATCCCAGCCCACCACCGAATCATCATGGCAGAACTT 
AspAlaTyrLysLysLysGlyLeuIleProAlaHisHisArgIleIleMetAlaGluLeu 
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GCCACCAAGAACTCACACTGGGTGGAAGTGGATACGTGGGAAAGTCTTCAGAAGGAGTGG 
AlaThrLysAsnSerHisTrpValGluValAspThrTrpGluSerLeuGlnLysGluTrp 
 
GTGGAGACTGTGAAGGTGCTCAGATACCATCAGGAGAAGCTGGCAACTGGCAGCTGCAGT 
ValGluThrValLysValLeuArgTyrHisGlnGluLysLeuAlaThrGlySerCysSer 
TACCCACAAAGCTCACCTGCACTGGAAAAGCCTGGGCGGAAGAGGAAGTGGGCTGATCAA 
TyrProGlnSerSerProAlaLeuGluLysProGlyArgLysArgLysTrpAlaAspGln 
  
AAGCAAGATTCTAGCCCACAGAAGCCCCAAGAGCCCAAACCAACAGGTGTGCCCAAGGTG  
LysGlnAspSerSerProGlnLysProGlnGluProLysProThrGlyValProLysVal 
  
AAATTGCTGTGTGGGGCAGATTTACTGGAGTCCTTCAGCGTGCCCAACTTGTGGAAGATG  
LysLeuLeuCysGlyAlaAspLeuLeuGluSerPheSerValProAsnLeuTrpLysMet 
  
GAGGACATCACGCAAATCGTGGCCAACTTTGGGCTCATCTGTATCACTCGGGCTGGCAGT  
GluAspIleThrGlnIleValAlaAsnPheGlyLeuIleCysIleThrArgAlaGlySer 
 
GACGCTCAGAAATTCATCTACGAGTCCGATGTGCTGTGGAGACATCAGAGCAACATCCAC 
AspAlaGlnLysPheIleTyrGluSerAspValLeuTrpArgHisGlnSerAsnIleHis 
 
CTGGTGAACGAGTGGATCACCAATGACATCTCGTCCACCAAGATCCGGAGGGCGCTCAGG  
LeuValAsnGluTrpIleThrAsnAspIleSerSerThrLysIleArgArgAlaLeuArg 
  
  161 
  181 
  201 
  221 
  241 
  261 
  281 
  301 
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AGGGGCCAGAGCATCCGCTACTTGGTACCGGACCTGGTCCAAGAGTACATTGAGAAGCAT 
ArgGlyGlnSerIleArgTyrLeuValProAspLeuValGlnGluTyrIleGluLysHis 
  
GAGCTGTACAACACGGAGAGCGAAGGCAGGAATGCTGGGGTCACCCTGGCTCCTCTGCAG  
GluLeuTyrAsnThrGluSerGluGlyArgAsnAlaGlyValThrLeuAlaProLeuGln 
  
AGGAACGCCGCAGAGGCCAAGCACAACCATTCCACTCTGTGA 
ArgAsnAlaAlaGluAlaLysHisAsnHisSerThrLeu*** 373 
  321 
  341 
  361 
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Figure 1.4 Scheme of the deleted region of Uch-l1 in gad mice. gad mutation is caused by 
an in-frame deletion including exon7 and exon 8 of Uchl1, encoding the ubiquitin carboxy-
terminal hydrolase l1.  
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Figure 1.4 Scheme of the deleted region of Uchl1 in gad mice. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deletion 
 
exon6 exon7 
 
exon8 
 
exon9 
 
exon6 
 
exon9 
 
exon7 exon8 
126bp 
 
+/+ 
gad / gad 
4.2kp 
1144bp 
764bp 
6F 
9R 
6F 9R 
 25
 
Figure 1.5 Four spectrally distinct XFPs serve as vital stains in transgenic mice. 
Neuromuscular junctions from thy1-YFP line H (a), thy1-GFP line H (b), thy1-CFP line 
D (c), and thy1-RFP line 8 (d) transgenic mice.  
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Figure 1.5 Four spectrally distinct XFPs serve as vital stains in transgenic mice. 
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2.1 Molecular and cellular biology 
2.1.1 Extraction of Genomic DNA and preparation of DNA agarose plugs for PFG.  
Solution DNA was extracted from mouse spleen or tail tip by using the Nucleon II kit 
(Amersham Pharmacia) (referred to Appendix 1) according to the manufacturer’s 
instructions. One-third of spleen was homogenized in 2.5 ml Reagent A (10 mM Tris-
HCl, 320 mM sucrose, 5 mM MgCl2, 1% (v/v) Triton X-100, pH 8.0) and spun down at 
3,000xg. Cell pellet was lysed in 0.5 ml Reagent B containing SDS (supplied by Nucleon 
II kit) with RNase A treatment (final concentration 400 ng/ml) at 37˚C for 30 minutes, 
deproteinized by adding 150 μl sodium perchlorate and extracted by adding 0.5 ml 
chloroform and 150 μl Nucleon resin (supplied by Nucleon II kit). Upper DNA phase was 
transferred to a clean tube and precipitated with 2 volumes of cold absolute ethanol. DNA 
pellet was washed once with 70% ethanol and suspended in 100-μl sterile water (a rough 
concentration of 0.25 μg/μl). For hard tissue preparation, half centimeter tail tip was 
lysed in 0.35 ml Reagent B containing SDS (supplied by Nucleon II kit) with proteinase 
K to a final concentration of 50 ng/ml, overnight, and deproteinized by adding 100 μl 
sodium perchlorate. DNAs were extracted by adding 0.6 ml chloroform and 150 μl 
Nucleon resin, Upper DNA phase was transferred to a clean tube and precipitated with 2 
volumes of cold absolute ethanol. DNA pellet was washed once with 70% ethanol and 
suspended in 40-μl sterile water (a rough concentration of 0.25 μg/μl).  
High Molecular weight DNA for pulsed-field gel electrophoresis (PFG) also was 
extracted from spleen as follows. Half a spleen was dissociated in 1ml of PBS by 
multiple passages through increasingly narrower needles (from 1.1 mm down to 0.6 mm) 
and strained through a Becton Dickinson cell strainer (70 μm).  The cells were mixed 
with an equal volume of 1% low-melting point agarose (Flowgen Lichfield, U. K.) in 
distilled water and poured into a Bio-Rad plug mould on ice (Bio-Rad, Richmond, CA). 
The embedded cells then were lysed by three overnight incubations in 0.5 M EDTA, 1% 
sodium-N-laurylsarcosine, and 25 μg/ml of proteinase K at 48˚C, washed three times in 
TrisּHCl (10 mM, pH 7.5) and stored long term in TrisּHCl (10 mM, pH 7.5) plus PMSF 
(0.04 mg/ml).    
2.1.2 Genotyping methods to track WldS triplication. 
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PCR. Wlds and 6J genomic DNA was extracted by using the Nucleon II kit (Amersham 
Pharmacia) (section 2.1.1 and Appendix 1) and used as template. WldF and WldR were 
used as primers: (WldF) 5’-CGTTGGCTCTAAGGACAGCAC-3’; (WldR) 5’-
CTGCAGCCCCCACCC CTT-3’. 
Amplification conditions are: 1 cycle of denaturation at 94˚C for 2 minutes; 35 cycles of 
(denaturation at 94˚C for 45 seconds; annealing at 60˚C for 45 seconds; extension at 72˚C 
for 45 seconds); and a final cycle of extension at 72˚C for 10 minutes. Reaction agents 
referred to Appendix 5. 
Southern blotting (refers to Appendix 6). To track the WldS triplication, genomic DNA 
extracts were digested by EcoRV at 37˚C overnight, and run on 1 % TAE gel overnight. 
The gel was denatured in 0.4 M NaOH with two changes at 30-minute intervals.  DNA on 
the gel was Southern-blotted overnight onto Hybond N+ (Amersham) in 0.4 M NaOH. 
Probe GS11 (sequence see below) was radiolabelled by using the Amersham Megaprime 
kit and [α-32P] dCTP (DuPont/NEN). Posthybridization washes were normally done at a 
stringency of 0.5 x standard saline citrate (SSC), 0.1% SDS. Radioactive filters were 
exposed to X-ray film (X-Ograph, Malmesbury, UK) for 24 hours at -80˚C or longer 
when necessary.  
Probe GS11 corresponds to nt.5370-6084 in Genbank entry AF260927 was amplified 
from WldS genomic DNA using primers WldF2 (5’-
ACATCATACATACTAGGTAAGC-3’) and WldR2 (5’-
AACTGGATTCTGAACTGATGT-3’). 
Pulsed-Field Gel Electrophoresis (refers to Appendix 7). Before digestion, agarose plugs 
(preparation described in 2.1.1) were equilibrated with three changes of 30ml of TrisּHCl 
(10 mM, pH 7.5), 1mM EDTA, and then with 1ml of the restriction buffer 3 (Invitrogen, 
USA). Thirty units of NotI in a volume of 100 μl was used to digest ½ fragments of plugs 
for 5 hours at 37ºC. Pulsed-field gel electrophoresis was performed in 0.5 X TBE (90 
mM Tris/64.6 mM boric acid/2.5 mM EDTA, pH 8.3) by using a Bio-Rad Chef-DR 
electrophoresis cell and running conditions of 6V/cm, 10ºC, switch times ramped from 20 
to 60 sec, and a run length of 22 hours. After electrophoresis the gel was depurinated for 
2 x 10 minutes in HCl (0.3% v/v), Southern-blotted and the DNA was hybridized with 
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the probe 2 (sequence see below), located centrally within the repeat unit (Figure 3.1) 
(hybridization procedure is the same as above in southern blotting). 
Probe2 was generated by primers WldF3 (5’-TGTAGGTCAACACCACCAAC-3’) and 
WldR3 (5’-TTCCCACGTATCCACTTCCA-3’) from WldS genomic DNA. 
2.1.3 Genotyping of transgenic mice and gad (gracile axonal dystrophy) mice. 
Transgenic mice N70-NLS and N70-NES: DNA was prepared from a 5-mm tail biopsy 
using the Nucleon II kit (Amersham Pharmacia, Freiburg, Germany) (Appendix 1). The 
~5 kb transgene coding region plus promoter region (constructs shown in Figure 6.1b and 
Figure 6.1c) was detected using Southern blotting of a HindIII single digest on Hybond 
N+ (Amersham Pharmacia) and hybridization with a corresponding 32P-labeled probe Hg 
(Probe Hg corresponds to nt.5370-6084 in Genbank entry AF260927, covers the full 
length sequence of WldS gene Ube4b/Nmnat). 
gad genotyping: For gad genotyping tail, genomic DNA was extracted at 3 weeks using 
the Nucleon II kit (Amersham Pharmacia)(section 2.1.1 and Appendix 1), digested with 
PvuII, and Southern blotted (See section 2.1.2 and Appendix 6).  It was then hybridized 
with a 32P labeled 764bp probe generated by PCR from gad homozygous genomic DNA 
using primers gadF (5’ATCCAGGCGGCCCATGACTC3’) and gadR 
(5’AGCTGCTTTGCAGAGAGCCA3’). Positively hybridizing fragments indicative of 
the gad (0.75 kb) and wild-type (1.6 kb) alleles were then identified by autoradiography.   
2.1.4 Generation of transgenic mice. 
Generation of transgenic mice expressing N70-NLS-Flag-tag.  
PCR: DNA encoding N70 (N-terminal 210 nucleotides of Ube4b/Nmnat) was amplified 
by PCR (refers to Appendix 5) from pHβAPr-1-WldS (Novagen, Germany), which was 
used as transgenic construct for expressing Ube4b/Nmnat (WldS gene)(Mack et al, 2001), 
using Platinum Pfx polymerase (Life Technologies, Karlsruhe, Germany). The primers 
were designed to contain a BamHI and a HindIII restriction site at the 5’ and 3’ ends 
flanking the N70 sequence. An arbitrary 4 or 5 base was added to 5’ end of each primer 
to facilitate cloning.  The amplification conditions are: 1 cycle of denaturation at 94˚C for 
2 minutes; 35 cycles of (denaturation at 94˚C for 45 seconds; annealing at 56˚C for 45 
seconds; extension at 72˚C for 45 seconds)(Appendix 5). Primers used are FT1A (5’ATC 
CCA AGC TTA ACC TTT CAC CAT TAA GAG GAA AGC GAT G3’) and N70-TGR 
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(5’ACG CGG ATC CCT GCT GCA CCT ATG GGG GA3’)(letters in bold are the 
restriction site of BamHI and HindIII and the start codon is underlined).  
Cloning: The amplified N70 flanked with recognition sequence of HindIII and BamHI 
was purified by phenol extraction (Appendix 8). N70 products were digested by 
BamHI/HindIII and ligated into downstream of the β-actin promoter in BamHI/HindIII 
double-digested pHβAPr-1 vector (Figure 6.1b). Ligation product was transformed into 
bacterial strain XL-10 Gold (Stratagene, Amsterdam, Netherlands). Transformants on LB 
agar plate with ampicillin (100 μl/ml) were screened using PCR (Appendix 10). The 
amplified products were analyzed by electrophoresis on a 1% agarose gel. Colonies that 
gave a PCR product around 210 bp were then chosen for plasmid isolation using Plasmid 
Mini Kit (Qiagen, Germany)(Appendix 2). Commercially synthesized and 
phosphorylated primers (the nuclear localization signal (NLS) of the SV40 large T 
antigen) (Invitrogen, Germany) flanked with restriction site of BamHI were digested by 
BamHI and ligated with BamHI-digested Flag-tag sequence at the C-terminal (sequence 
see Figure 2.1)(ligation refers to Appendix 9). Such ligation products were further ligated 
downstream of a BamHI single digested β-actin/pHβAPr-1-N70 backbone (construct see 
Figure 6.1b). Ligation products were transformed into bacterial strain XL-10 Gold 
(Stratagene, Amsterdam, Netherlands) and transformants on LB agar plate with 
ampicillin (100 μl/ml) were screened using PCR (Appendix 10). The amplified products 
were analyzed by electrophoresis on a 1% agarose gel. Colonies that gave a PCR product 
around 300 bp were then chosen for plasmid isolation using Plasmid Mini Kit (Qiagen, 
Germany)(Appendix 2). The orientation and sequence of insert (N70 / 3 x NLS / Flag-tag) 
were confirmed by DNA-sequencing service in ZMMK (center of molecular medicine in 
Köln) (ABI Prism 377 DNA-sequencer, Applied Biosystems).  
Transfection and pronuclear injection: The construct was transfected to COS-7 cells to 
confirm the nuclear protein location (see 2.1.9). A 5-kb fragment containing promoter, 
N70-NLS-Flagtag, and polyadenylation signal was released using NdeI and EcoRI and 
gel-purified using QIAquick extraction (Qiagen, Hilden, Germany) (Appendix 3). 
Pronuclear injection into CBA x C57 F1 single-cell embryos (G. Kollias, Vari, Greece) 
resulted in one founder from 23 pups that were screened by Southern blotting (refers to 
genotyping transgenic mice in 2.1.3).    
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Generation of transgenic mice expressing N70-NES-Flag-tag.  
PCR: DNA encoding N70 (N-terminal 210 nucleotides of Ube4b/Nmnat) was amplified 
by PCR (refers to Appendix 5) from pHβAPr-1-WldS (Novagen, Germany), which was 
used as transgenic construct for expressing Ube4b/Nmnat (WldS gene)(see above), using 
Platinum Pfx polymerase (Life Technologies, Karlsruhe, Germany). The primers were 
designed to contain a BamHI and a HindIII restriction site at the 5’ and 3’ ends flanking 
the N70 sequence. An arbitrary 4 or 5 base was added to 5’ end of each primer to 
facilitate cloning.  The amplification conditions are: 1 cycle of denaturation at 94˚C for 2 
minutes; 35 cycles of (denaturation at 94˚C for 45 seconds; annealing at 56˚C for 45 
seconds; extension at 72˚C for 45 seconds)(Appendix 5). Primers used are FT1A (5’ATC 
CCA AGC TTA ACC TTT CAC CAT TAA GAG GAA AGC GAT G3’) and N70-TGR 
(5’ACG CGG ATC CCT GCT GCA CCT ATG GGG GA3’)(letters in bold are the 
restriction site of BamHI and HindIII and the start codon is underlined).  
Cloning: The amplified N70 flanked with recognition sequence of HindIII and BamHI 
was purified by phenol extraction (Appendix 8). N70 products were digested by 
BamHI/HindIII and ligated into downstream of the β-actin promoter in BamHI/HindIII 
double-digested pHβAPr-1 vector (Figure 6.1c). Ligation products were then transformed 
into bacterial strain XL-10 Gold (Stratagene, Amsterdam, Netherlands). Transformants 
on LB agar plate with ampicillin (100 μl/ml) were screened using PCR (Appendix 10). 
The amplified products were analyzed by electrophoresis on a 1% agarose gel. Colonies 
that gave a PCR product around 210 bp were then chosen for plasmid isolation using 
Plasmid Mini Kit (Qiagen, Germany)(Appendix 2). Commercial synthesized and 
phosphorylated primers (the nuclear export signal (NES) of HIV-Rev (Invitrogen, 
Germany)(Fukuda et al, 1997; Wen et al, 1995) flanked with restriction site of BamHI 
were digested by BamHI and ligated with BamHI-digested Flag-tag sequence at the C-
terminal (sequence see Figure 2.1) (ligation refers to Appendix 9). Ligation products 
were then cloned downstream of a BamHI single digested β-actin/pHβAPr-1-N70 
backbone (construct see Figure 6.1c). Ligation products were transformed into bacterial 
strain XL-10 Gold (Stratagene, Amsterdam, Netherlands) and transformants on LB agar 
plate with ampicillin (100 μl/ml) were screened using PCR (Appendix 10). The amplified 
products were analyzed by electrophoresis on a 1% agarose gel. Colonies that gave a 
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PCR product around 300 bp were then chosen for plasmid isolation using Plasmid Mini 
Kit (Qiagen, Germany)(Appendix 2). The orientation and sequence of insert (N70 / NES / 
Flag-tag) were confirmed by DNA-sequencing service in ZMMK (center of molecular 
medicine in Köln) (ABI Prism 377 DNA-sequencer, Applied Biosystems).  
Transfection and pronuclear injection: The construct was transfected to COS-7 cells to 
confirm the cytoplasmic localization (see 2.1.9). A 5-kb fragment containing promoter, 
N70-NES-Flagtag, and polyadenylation signal was released using NdeI and EcoRI and 
gel-purified using QIAquick extraction (Qiagen, Hilden, Germany)(Appendix 3).  
Pronuclear injection into CBA x C57 F1 single-cell embryos (G. Kollias, Vari, Greece) 
resulted in 8 founder from 68 pups which were screened by Southern blotting and PCR 
(refers to genotyping transgenic mice in 2.1.3).   
2.1.5 Cloning and expression of recombinant proteins. 
N-terminal 210 nucleotides (N70) of chimeric gene (WldS) was PCR-amplified from 
transgene construct using Pfx polymerase (Life Technologies) (Primers see below) (PCR 
refers to Appendix 5). The primers were designed to contain a NheI and a XhoI restriction 
site at the 5’ and 3’ ends flanking the N70 sequence. An arbitrary 4 or 5 base was added 
to 5’ end of each primer to facilitate cloning.  PCR products were purified by phenol 
extraction (Appendix 8). N70 double-digested by NheI/XhoI was ligated into NheI/XhoI 
double-digested pET-28b (+) vector (Novagen, Schwalbach, Germany) (Figure 2.2 and 
ligation reaction see Appendix 8) and transformed into high transformation efficiency 
strain, XL-10 Gold (Stratagene, Amsterdam, Netherlands). Plasmids isolated using the 
Plasmid Mini Kit (Qiagen, Germany)(Appendix 2) and the orientation and sequence of 
the insert were confirmed by DNA-sequencing service in ZMMK (Center of Molecular 
Medicine in Köln) (ABI Prism 377 DNA-sequencer, Applied Biosystems). The plasmids 
containing N70 insert were retransformed into bacterial strain BL21 (DE3) (Novagen, 
Germany) because BL21 (DE3) is ideal for high-level protein expression using T7 RNA 
polymerase promoter, easy induction by Isopropyl-1-thio-β-D-galactopyranoside (IPTG), 
and with tighter control of protein expression for expression of toxic proteins. Protein 
expression was induced with 1mM IPTG for 3h at OD600=0.8 (Optimization of conditions 
for N70 expression see Appendix 11). 
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Full length chimeric gene (WldS) was PCR-amplified from transgene construct using Pfx 
polymerase (Life Technologies) (Primers see below) (PCR refers to Appendix 5). The 
primers were designed to contain a NheI and a XhoI restriction site at the 5’ and 3’ ends 
flanking the N70 sequence. Arbitrary 3 or 5 bases were added to 5’ end of each primer to 
facilitate cloning. Full length chimeric gene double-digested by NheI/XhoI were ligated 
into NheI/XhoI double-digested pET-28b (+) vector (Novagen, Schwalbach, 
Germany)(Figure 2.2 and ligation reaction see Appendix 8) and transformed into XL-10 
Gold (Stratagene, Amsterdam, Netherlands). Plasmids isolated using the Plasmid Mini 
Kit (Qiagen, Germany)(Appendix 2) and the orientation and sequence of insert were 
confirmed by DNA-sequencing service in ZMMK (center of molecular medicine in Köln) 
(ABI Prism 377 DNA-sequencer, Applied Biosystems). The plasmids containing 
chimeric gene insert were retransformed into BL21 (DE3) (Novagen, Germany). Protein 
expression was induced with 1mM IPTG for 3h at OD600=0.8 (Optimization of conditions 
for N70 expression see Appendix 11).  
The procedure of purifying recombinant chimeric protein refers to that for recombinant 
N70 protein in 2.1.6. 
Primers for N70 were 5’-GACTAGCTAGCATGGAGGAGCTGAGCGCTGAC-3’ 
(NheI restriction sites were indicated in bold, the start codons were underlined) and 5’-
ATCCGCTCGAGCTAGTCTGCTGCACCTATGGGGGA-3’ (XhoI restriction sites 
were indicated in bold).   
Primers for full-length chimeric gene were 5’-
GACTAGCTAGCATGGAGGAGCTGAGCGCTGAC-3’ (NheI restriction sites were 
indicated in bold, the start codons were underlined) and 5’-
CGCCTCGAGTCACAGAGTGGAATGGTTGTGC-3’ (XhoI restriction sites were 
indicated in bold).  
2.1.6 Purification of recombinant protein (N70 and WldS)  
The N70 (or WldS protein) bacterial pellet was resuspended in native binding buffer (20 
mM sodium phosphate, 500 mM sodium chloride pH7.8, 100μg/ml egg white lysozyme), 
sonicated on ice (6 x 15s with 15-s intervals) and centrifuged at 4˚C (3,000 g, 15 min). 
N70 was purified using a ProBondTM Resin column (Invitrogen, Groningen, 
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Netherlands)(refersto Appendix 4) and concentrated using a YM-3 Centricon centrifugal 
filter (Millipore, Bedford, Massachusetts).  
2.1.7 Generation of polyclonal antisera 
Antisera (60ml) were raised commercially (Eurogentec, Belgium) by intradermal 
immunization of rabbits with 20-100 mg of recombinant N70 / per injection per animal at 
days 14, 28 and 56, and a final bleed at 80 days. Antigens (recombinant N70) were 
emulsified with complete Freund’s adjuvant for the first injection, and with incomplete 
Freund’s adjuvant for the booster injections. Small volume of bleeds (2-3 ml) were taken 
at days 0, 38 and 66 and shipped on dry ice to us for antibody production test. The 
possibility of polyclonal antibody against recombinant N70 was tested by Western blot 
(refers to 2.1.8).  
For affinity purification 500 μg N70 protein bound to ProBond resin (2 ml wet volume) 
was blocked with 5% (w/v) dried skimmed milk powder plus 1% (w/v) BSA in native 
binding buffer. Resin was incubated with crude antiserum (2 ml in 8 ml binding buffer), 
and washed with 10 bed volumes binding buffer. Specific antibodies, binding only WldS 
protein and Ube4b, were eluted with 100 mM ethanolamine (pH 11.5), neutralized with 
1.5 M Tris and dialyzed against PBS. (Dr. Till Mack in the lab did this affinity 
purification). 
2.1.8 Western blotting (Appendix 12) 
Preparation of samples for western blotting 
The expression level of proteins of interest was analysed in mouse brains, which were 
ground to a fine powder under liquid nitrogen and a few millgrammes placed on ice in 20 
vol of BUST buffer (60mM Tris-Hcl (pH 6.8), 8.0M Urea, 2% (w/v) SDS, and 2% (v/v) 
2-mercaptoethanol) for 4 hours on ice and then manually homogenized. The degree of 
preservation of heavy neurofilament protein was determined in the distal segment of 
lesioned sciatic nerves homogenized in 20 volumes of the same buffer. Segments of 
lumbar spinal cord (cut into fine pieces) and combined dorsal root ganglia (L4-L5) for 
checking the WldS protein expression level were placed on ice in 20 vol of BUST buffer 
for 4 hours with occasional manual homogenization. 
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Proteins separated by SDS-Polyacrylamide gels (refers to Appendix 13) and transferred 
to nitrocellulose filter (refers to Appendix 12)  
The samples were mixed with half volume of 3-x SDS-PAGE buffer. Proteins were 
separated using standard SDS-PAGE (8-15% (w/v) acrylamide) depending on the 
molecular weight of proteins: 40~100 kDa, 8% (w/v) acrylamide; 20~70 kDa, 10 or 12% 
(w/v) acrylamide; 10~40 kDa, 15% (w/v) acrylamide. Proteins on SDS-PAGE were 
transferred onto nitrocellulose filters using a semi-dry blotter (BioRad, 
Germany)(Appendix 12). Membrane was incubated in Ponceau S staining solution (0.5% 
(w/v) Ponceau S (Sigma, Germany); 1% (v/v) glacial acetic acid) with gentle agitation for 
2 minutes, and then destained in distilled water until bands are visible to check that 
proteins of different sizes have been transferred uniformly to the membrane. 
Immunoblotting 
Membranes were incubated for 1h in blocking buffer (5% skimmed milk) at room 
temperature, and then incubated with primary antibodies (dilution of primary antibody 
according to requirement) in the same blocking buffer overnight with gentle shaking at 4 
°C. After washed twice for 10 minutes each in PBS-Tween (0.05% Tweenâ20) buffer at 
room temperature, membrane was incubated with secondary antibody coupled to 
horseradish peroxidase (goat-anti-mouse 1:2000, goat-anti-rabbit 1:2000; Dianova, 
Hamburg, Germany) for 1 h at room temperature.  Signals were detected by enhanced 
chemiluminescence (ECL-detection; Amersham Pharmacia). 
Blots could be stripped by stripping buffer (2% SDS, 100 mM b-mercaptoethanol, 50 
mM Tris, pH 6.8), which can subsequently be reprobed with a different antibody.  
2.1.9 Cells transfection and fixation for immunofluorescence examination.  
Maintenance of stable cell line: COS-7 cells were maintained in DulBecco’s MEM (D-
MEM) with Glutamax-1 (Invitrogen, GIBCO) containing 10% fetal calf serum (FCS) at 
37˚C in 5% CO2 in a humidified incubator, and passaged once or twice per week at 1:10 
dilution. Cells (~ 2x105) were then seeded to a 6 x well plate in D-MEM medium with 
FCS and incubated at 37˚C in a CO2 incubator the day before transfection.  
Transfection: Transient transfections were carried out with Lipofectamine PLUSTM 
(Invitrogen Life Technologies). Two solutions were prepared before transfection: 1) 
diluted 4 μl of LipofectAMINE reagent into 100 μl specialized medium (reduced serum 
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medium) OPTI-MEMTM  (Invitrogen, GIBCO) for facilitating lipid-mediated transfection, 
and incubated for 5 minutes at room temperature; 2) diluted ~1 μg DNA into 100 μl 
OPTI-MEMTM  (Invitrogen, GIBCO), 4 μl PLUS reagent into DNA and mixed it. The 
solution 1) was added rapidly into the solution 2) and mixed. Such transfection 
complexes were incubated for 20 minutes at room temperature. The old medium was 
removed from the cells and replaced by 800 μl transfection medium (OPTI-MEMTM). 
The transfection complexes (DNA-PLUS-LipofectAMINE) were added to cells and left 
to incubate at 37˚C at 5% CO2 for 3 hours. The medium with the complexes was removed 
and 2 ml fresh D-MEM with 10% FCS was added to the cells with an overnight 
incubation. 
Fixation of transfected cells: The cells were fixed in 4% paraformaldehyde (PFA)/0.05% 
glutaraldehyde in PBS for 30 minutes, washed twice with PBS, and finally permeabilized 
in 0.1% Triton in PBS for 10 minutes. Low concentration of glutaraldehyde is to facilitate 
better cell fixation without destroying epitopes. 
Immunostaining: fixed cells were blocked in 5% FCS in PBS for half an hour, and 
incubated at room temperature in anti-Flag M2 monoclonal antibody (1:100 in the same 
buffer) (Stratagene, USA) for 1 hour. Cells were then washed twice in PBS and incubated 
in Texas RedÒ X-goat anti-mouse IgG (H+L) (1:200) (Molecular Probes, Eugene, Oregon, 
USA) at room temperature for 45 minutes, washed twice with PBS, and incubated with 
mounting medium with DAPI (Vector Laboratories, USA) 5 minutes for nuclear staining. 
After washing twice with PBS, fixed cells were mounted with mounting medium (Vector 
Laboratories, USA) and covered with cover slip. 
      
2.2 Animals breeding protocols and behavioral analysis 
2.2.1 Animal breeding protocols 
Crossing mouse model (P0-/- mouse) of myelin-related peripheral neuropathy with WldS. 
(done in the collaborator Martini’s lab) 
Homozygous C57BL/WldS mutants were obtained from Harlan-Winkelmann (Borchen, 
Germany) and cross-bred with heterozygous P0 mutants. According to Mendelian law, 
the individuals of the F1 generation were expected to consist exclusively of mice 
heterozygous for the WldS mutation. All of these individuals were genotyped for the P0 
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mutation by conventional PCR as described previously (Schmid et al, 2000), and 
individuals heterozygously deficient for P0 were intercrossed, leading to progenies with 
homozygous, heterozygous, and no P0 deficiency. Pulsed-field gel electrophoresis was 
used to genotype for WldS status (see detail in 2.1.2).  
Crossing Uchl1gad/gad (gracile axonal dystrophy mice)(refers to as gad-/- below) with WldS. 
In the following text, gad+/+, gad+/- and gad-/- refer to wild type, heterozygous and 
homozygous gad mice respectively. 
Homozygous C57BL/WldS/S (refers to as WldS/S below) mutants were obtained from 
Harlan-Orlac (Netherland) and crossbred with heterozygous Uch-l1gad/+ (refers to as gad+/- 
below) imported from Japan. According to Mendelian law, the individuals of the F1 
generation were expected to consist exclusively of mice heterozygous for the WldS 
mutation. All of these individuals were genotyped for the gad status by Southern blotting 
(see section 2.1.2)(Appendix 6), and double heterozygotes (gad+/-/WldS/+) were 
intercrossed, leading to progenies with gad+/+, gad+/- and gad-/-. Only gad-/- was chosen 
for behavioral and pathological analysis (gad genotyping see 2.1.3). WldS genotype was 
determined postmortem by pulsed-field gel electrophoresis of spleen DNA (Mi et al, 
2002)(see detail in 2.1.2)(Appendix 7). 
For assessment of Wallerian degeneration (section 5.2.1), heterozygous YFP-H mice 
were obtained from The Jackson Laboratories, Bar Harbor, Maine and mated with 
gad/WldS double heterozygotes to produce triple heterozygotes.  These were then mated 
to gad/WldS double heterozygotes and YFP-H positive offspring genotyped for gad and 
WldS to identify gad homozygotes that were heterozygous for both WldS and YFP-H. The 
genotyping method for inheritance of the YFP-H transgene refers to below.   
Crossing transgenic N70-NLS and N70-NES with YFP-H expressing mice. 
Transgenic N70-NLS or transgenic N70–NES were crossbred with YFP-H expressing 
mice (Jackson Laboratories, Bar Harbour, ME, USA). To genotype for inheritance of the 
YFP-H transgene, the skin of a 1-2 mm ear punch at 21 days was pulled apart and 
fluorescent axons or neuronal cell bodies identified using a Zeiss Axiovert S100 inverted 
fluorescent microscope through the FITC filter. YFP-expression in axons was used as a 
tool to visualize the preservation of axons directly.     
N70-NLS or N70-NES status was confirmed by Southern blotting (see section 2.1.3). 
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2.2.2 Rotarod analysis. 
Tests were performed blind to the WldS genotype.   
For the accelerating Rotarod (Model 7650, UGO BASILE), mice were trained twice for 
five minutes at constant speed (3.5 rpm) prior to five repeated testing at accelerating 
speed from 3.5 rpm to 35 rpm over five minutes.  A minimum of 45 minutes recovery 
time was allowed between each trial.  The median time in seconds to fall off from the 
Rotarod was taken as a measure of the maximum running speed achieved and the test 
repeated weekly from 9 to 18 weeks.  Although mice may fall from the Rotarod for many 
reasons, it was clear from our observations that progressive hind limb paralysis was the 
primary cause for the gad mice to fall. This became evident also during normal walking 
for mice scoring below approximately 100 seconds. Wild-type mice typically remained 
on the Rotarod for the full 300 seconds and the WldS mutation did not alter this.   
2.2.3 Clasping. 
In the clasping test, the mouse was suspended by the tail more than 50 cm from any 
surface.  Clasping time within a 1-minute test was scored as flexing or folding of the hind 
limbs tightly towards the trunk plus any spasmodic stretching.  Mice were examined once 
per week through the period from 6 weeks to 16 weeks.  No wild-type mice clasped, 
regardless of the presence of the WldS mutation.2.2.4 Foot splay test. 
The foot splay test (Norreel et al, 2001) was used to estimate the reflex reaction speed of 
the hind limbs. Mice were gently taken by the neck and tail, the plantar surface of their 
hind feet painted using a non-toxic children's painting set, and the mouse released from a 
height of 15 cm to land on white paper.  Wild-type mice bring their legs together during 
descent to land like a gymnast, whereas advanced gad mice fail to do this and land with 
their feet far apart. The distance between the two hind heels was averaged from 10 
successive trials on each testing date (9 weeks and 13 weeks).    
2.2.5 Peripheral nerves lesion (PNL). 
Six- to eleven-week-old mice were anesthetized intraperitoneally with Ketanest 
(100mg/kg; Bayer, Leverkusen, Germany) and Rompun (5 mg/kg; Parke Davis/Pfizer, 
Karlsruhe, Germany). Right sciatic nerves (upper thigh) were transected and the wounds 
were closed with single sutures. Two to three days later (for transgenic N70-NLS and 
transgenic N70-NES), mice were killed, the swollen first 2 mm of the distal nerve was 
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discarded, the next 2 mm was used for Western blot, and further down tibial nerve (one 
branch of sciatic nerve at the lower thigh) was taken for fluorescence examination under 
light microscopy (the preparation of YFP nerves in section 2.2.6). 
2.2.6 Processing YFP nerves. 
Tibial and/or sciatic nerves were dissected from mouse (gad+/+/WldS/S or gad+/+/Wld+/+; 
gad wt/Wld+/+; transgenic N70-NLS; transgenic N70-NES) with a minimum of attached 
adipose tissue and stretched approximately 10% by pinning them out on a Sylgard dish 
(Du Pont). Nerves were then fixed with 4 % paraformaldehyde (PFA) (BDH laboratory, 
England) in 0.1 M PBS in dark for 1 hour, further incubated in 1 % Triton X-100 (Sigma, 
Germany) in 0.1 M PBS for 10 minutes in dark. After 3 times wash with PBS for 5 
minutes each, nerves were mounted in Vectashield (Vector Laboratories, USA) on a glass 
slide and stored dark at 4°C.  View it on fluorescent microscope with standard FITC filter.  
  
2.3 Histological analysis  
2.3.1 Paraffin embedding of brain / spinal cord.  
Mice aged 126-130 d were anaesthetized using Ketanest and Rompun (100 mg/kg and 5 
mg/kg i.p. respectively) or a higher dose as required for deep terminal anaesthesia. After 
sternotomy, mice were killed by cardiac puncture and instantly intracardially perfused 
first with a solution containing 10 000 I.E. / l heparin (Liquemin N 25000, Hoffmann-La 
Roche) and 1% procainhydrochloride in 0.1M PBS (phosphate buffered saline) for 30 
seconds and then with fixative (4% paraformaldehyde in 0.1M PBS) for 10 minutes.    
(Done by lab fellows Bogdan Beirowski and Dr. Robert Adalbert). Brain and spinal cord 
were carefully removed and fixed in 4% PFA/0.1M PBS overnight, with extensively 
buffer (0.1M PBS)-washing after fixation. Samples were then taken through a graded 
ethanol series for 3 days: 50% ethanol – 70% ethanol – 90% ethanol; followed by 
incubation in isopropyl alcohol overnight, chloroform overnight, and liquid paraffin 
overnight at 4ºC. The samples were then embedded in paraffin and harden in paraffin 
molds with ice. 6μm sections were taken on microtome (Type HM355, Microm GMBH) 
and mounted either on glass slides (Engelbrecht, Germany) for H&E staining or on same 
type of slides but coated with poly-L-Lysine for immunocytochemistry.  
2.3.2 Haematoxylin / eosin staining (H&E). 
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6 µm sections were deparaffinized in Xylol (Carl-Roth, Germany) for 10 minutes, 
rehydrated in a descending ethanol series and rinsed in deionized H2O for 1 minute.  
Sections were placed in Hematoxylin for 5 minutes, rinsed in tap water for 1 minute to 
allow stain to develop and then placed in eosin for 2 minutes, dehydrated and mounted in 
Entellan resin (Merck, Germany).  The occurrence of clearly detectable eosinophilic 
spheroids, indicative of dystrophic axons (Yamazaki et al, 1998; Mukoyama et al, 1989; 
Kikuchi et al, 1990) was quantified in approximately 90 sections from gracile nucleus 
and approximately 30 sections from cervical gracile fascicle so that irregular results due 
to random deviations in spheroid numbers could be ruled out. H&E stained axonal 
spheroids were generally eosinophilic and appeared with a round or oval shape. They 
varied in diameter (5-50 µm) and sometimes reached a size larger than the nerve cells in 
gracile nucleus. 
2.3.3 Luxol fast blue staining. 
6 μm paraffin sections on poly-L-Lysine coated slides were deparaffinized in Xylol 
(Carl-Roth, Germany) for 15 minutes, and processed twice through 100% ethanol for 2 
minutes each and a few seconds in 96% ethanol. Slides were transferred to Luxol fast 
blue solution (Luxol fast blue MBS chroma 0.1g (Merck, Germany); ethanol 96% 100ml; 
acetic acid 10% 0.5ml) and incubated at 60˚ C for 5 hours. Finally, sections were rinsed 
in 95% ethanol and distilled water for 1 minute each, dipped in a 0.05% 
Lithiumcarbonate (Merck, Germany) for 1 minute, and differentiated in 70% ethanol for 
another 1 minute. After rinsed in distilled water, sections were examined under light 
microscope for suitable differentiation between white and gray matter. Repeat the 
differentiation steps (1 minute in 0.05% Lithiumcarbonate and 1 minute in 70% ethanol) 
if necessary. Slides were then put into nuclear fast red staining solution (Aluminum 
sulfate 5% w/v; nuclear red 0.1% w/v; dH2O 100 ml) for 10 minutes, followed by 
through distilled H2O, 90% ethanol and 100% ethanol for 1 minute each. After putting in 
Xylol for 5 minutes, slides were covered by clover slips using Entellan (Merck, Germany) 
and left dry overnight in the hood.  
Slides were examined under light microscopy (Nilcon Eclipse E200) for blue myelin 
staining and the density of blue staining was evaluated by Bioscan OPTIMAS 6.0 
(Optimas Corp. Washington, USA) according to manufacturer’s instructions. For 
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densitometric quantification, mean gray values were obtained for circumscribed areas of 
interest using a 3-chip monochrome CCD camera, and the background gray value (tissue-
free area) was subtracted. Since demyelination occurs selectively in the gracile tract and 
not in the cuneate tract of gad mice by 126-130 d (Mukoyama, et al, 1989 and our own 
observations) we used cuneate fascicle as a reference area and expressed LFB staining in 
gracile tract as a percentage of that in cuneate tract. We applied this procedure to 
representative LFB stained sections of cranial gracile tract: two sections from level 
C2/C3 representing cervical gracile fascicle and two sections from level 535 representing 
gracile nucleus (Sidman et al, 1971)(Densitometric quantification was done by lab fellow 
Bogdan Beirowski). 
2.3.4 Anti-GFAP (Glial fibrillary acidic protein) immunostaining. 
Deparaffinizing: Slides were heated at 60˚C for 30 minutes, then processed through the 
following steps for 5 minutes each: Xylol – Xylol – 100% ethanol – 90% ethanol – 70% 
ethanol – 50% ethanol - dH2O. Then slides were stored in 0.05 M TBS until usage.   
Immunostaining: 6 μm paraffin sections on poly-L-Lysine coated slides were encircled 
with DAKO PAP-Pen and incubated in 0.05M TBS. After 10 minutes incubation with 
cell penetration solution (0.5 M NH4Cl plus 0.25% Triton in 0.05M TBS), sections were 
washed twice with 0.05 M TBS. After 20 minutes incubation in 1.2 % H2O2 v/v in 
methanol and 2 times washed with 0.05 M TBS, sections were blocked by 5% w/v BSA 
in 0.05M TBS for 60 minutes. Then sections were incubated with anti-GFAP antibody 
(1:400 dilution) (Progen, Germany) at 4˚C overnight. After washing 4 times with 0.05M 
TBS, sections were incubated with goat anti-guinea pig globulin biotin conjugate (1:400 
dilution) (Sigma, Germany) in 0.05M TBS for 1 hour. Sections were then washed again 4 
times with 0.05M TBS, and incubated with avidin-coupled horseradish-peroxidase-
complex (1:200 dilution) in 0.05M TBS for 1 hour. After 4 times wash with 0.05M TBS, 
sections were developed in filtered DAB (diaminobenzidine) solution (0.1 M PB pH7.4, 
15ml; DAB 0.05g/ml, 150ml; NH4Cl 0.04g/ml, 150ml; NiSO4 x 6 H2O 0.013g/ml, 300ml; 
10% b-D-Glucose 0.1g/ml 300ml; Glucose-Oxidase 1.2 mg/ml, 50ml) for 25 minutes.      
Dehydration and mounting: sections were dehydrated by through distilled H2O and a 
grade series of ethanol for 5 minutes each: 50%, 70%, 90% and 100%.  After putting into 
Xylol (Carl-Roth, Germany) for 5 minutes, slides were covered by clover slips using 
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Entellan (Merck, Germany) and left dry overnight in a fume hood. Quantification was 
similar to that described for LFB densitometry. GFAP immunostaining intensities in 
cranial gracile tract sections were expressed as percentage of GFAP staining intensity in 
wild-type sections at the same coronal level. We applied GFAP densitometry on 
representative cranial gracile tract sections from each examined mouse: two sections 
from level C2/C3 representing cervical gracile fascicle and two sections from level 535 
representing gracile nucleus (Sidman et al., 1971)(Densitometric quantification was done 
by lab fellow Bogdan). 
2.3.5 Statistical analysis of histopathological results. 
All data (axonal spheroid numbers, TV-densitometry intensities) are presented as mean ± 
SD for the examined genotype groups. Data analysis was performed using PRISM (done 
by Dr. Michael Coleman) for Macintosh, SPSS for Windows (done by lab fellow Bogdan 
Beirowski) or Microsoft Excel including Student’s t-test calculations for paired and 
unpaired data, where appropriate. Significance was considered at a p value < 0.05 and 
high significance at a p value < 0.01. 
2.3.6 Analysis of neuromuscular pathology (done by collaborator Dr. Ribchester’s 
lab in Edinburgh). 
Mice were killed by cervical dislocation and lumbrical muscles immediately dissected 
under oxygenated Ringer solution. Fixation, immunocytochemistry and signal imaging 
were then carried out as previously described (Gillingwater et al, 2002). The denervation 
rate was determined by counting 100-200 endplates in each of 2-3 lumbrical muscles and 
the mean value taken for each mouse. 
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Figure 2.1 Sequence of NLS (nuclear localization signal), NES (nuclear export signal) 
and Flag-tag used in generation of transgenic mice in 2.1.7. The dash ‘-‘ indicates the 
corresponding sequence of NLS or NES. Flagtag is indicated by blue blocks. 4 (for NLS) 
or 3 (for NES) amino acids are used as ‘Spacer’ (which links 3 x NLS or NES and 
Flagtag) to facilitate the reorganization of Flag tag by anti-Flag antibody (Stratagene, 
USA).  
3 x NLS – Flag tag: 
5’GATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAA 
 AspProLysLysLysArgLysValAspProLysLysLysArgLysValAspProLys           
AAGAAGAGAAAGGTAGATACGGCAGCAGACTACAAGGACGATGACGACAAGTGA3’ 
LysLysArgLysVal            AspTyrLysAspAspAspAspLys*Stop                  
 
NES-Flag tag: 
 
5’CTGCAACTGCCGCCCCTGGAACGGCTGACGCTGCAAGGCGCA GACTACAAGGACGAT 
  LeuGlnLeuProProLeuGluArgLeuThrLeu         AspTyrLysAspAsp 
    
GACGACAAGTGA 
AspAspLys*Stop 
 
NLS1 NLS2 NLS3 
Spacer 
Flagtag 
Spacer NES 
Flagtag 
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Figure 2.2 pET-28 a-c (+) vectors map. The pET-28 b (+) vectors carry an N-terminal 
His×Tagâ/thrombin/T7×Tagâ configuration plus an optional C-terminal His×Tag sequence. 
The cloning/expression region of the coding strand transcribed by T7 RNA polymerase is 
shown as well. The NheI and XhoI restriction sites were chosen for cloning. 
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Figure 2.2 
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Figure 2.3 Abnormal limbs clasping in mice. Mouse clasps hind-limbs upon suspension 
by the tail (indicated by arrow).  A) Normal control mouse spreads its hindlimbs when 
suspended by the tail. B) Mouse clasps its hind-limbs (Probst et al, 2000).  
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APPENDIX  
1. Principle of Nucleon II Kit (Amersham Pharmacia) for genomic DNA 
extraction 
Cells and nuclei from either soft tissue (spleen) or hard tissue (tail tip) were lysed by 
SDS, proteins precipitated with sodium perchlorate, removed with chloroform 
treatment and finally bound to the nucleon resin (supplied by the Nucleon II kit). 
DNA was then precipitated by absolute ethanol. DNAs were dissolved in distilled 
H2O for future use. 
2. Principle of Plasmid Mini Kit (Qiagen, Germany) for plasmid purification 
The principle is based on a modified alkaline lysis procedure, followed by binding of 
plasmid DNA to Qiagen Anion-Exchange Resin under appropriate low-salt and pH 
conditions. RNA, proteins, dyes, and low-molecular-weight impurities are removed 
by a medium-salt wash. Plasmid DNA is eluted in a high-salt buffer and then 
concentrated and desalted by isopropanol precipitation. 
3. Principle of QIAquick extraction (Qiagen, Hilden, Germany) 
DNAs were recovered efficiently by binding to a uniquely-designed silica-gel in the 
presence of high salt while contaminants pass through the column; impurities are 
efficiently washed away by ethanol-containing buffer and the pure DNA is eluted 
with distilled H2O. 
4. Principle of ProBondTM Resin column (Invitrogen, Groningen, Netherlands) 
ProBondTM resin is precharged with Ni2+ ions which has high affinity for recombinant 
fusion proteins that have been tagged with 6 x His-residues. Proteins with six 
histidine residues bound to the resin can be eluted with either low pH buffer or by 
competition with imidazole. The binding capacity of resin is 1-5 mg of protein per ml 
of resin.  
5. Reagents for PCR 
PCR is used to amplify a segment of DNA that lies between two regions of known 
sequence. Primers used in PCR were oligonucleotides that are complementary to 
sequences lying on opposite strands of the template DNA and flanking the segment of 
amplified DNA. PCR was typically performed in a total volume of 50 μl containing 1 
x amplification buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 1-μM primers, 50 ng 
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templates DNA and 2.5 units Taq DNA polymerase (Gibco-BRL, USA) or Platinum 
Pfx polymerase (Life Technologies, Karlsruhe, Germany) (with high reading-proof 
capacity). A programmable Thermal Cycler (Mastercycler gradient, Eppendorf, 
Germany) was used. 
6. Principle for Southern blotting 
Southern blotting is used to localize the particular sequences within genomic DNA 
(Southern, 1975). Genomic DNA is digested with one or more restriction enzymes, 
and the resulting fragments are separated according to size by electrophoresis through 
an agarose gel. The DNA is then denatured in situ by 0.4 M NaOH and transferred 
from the gel to a solid support such as positive charged nylon membrane. The DNA 
attached to the filter is hybridized to 32P-radiolabeled DNA or RNA, unbound probe 
removed by washing and autoradiography is used to locate the positions of bands 
complementary to the probe. 
7. Pulsed-Field Gel Electrophoresis 
All linear double-stranded DNA molecules that are larger than a certain size migrate 
through agarose gels at the same rate. To solve such limit of resolution, pulsed fields 
of alternating direction is applied to a gel: large DNA molecules have to reorient 
themselves along the new axis of the electric field instead of migrating ‘end-on’ 
through the matrix in normal agarose gel apparatus. The larger the DNA molecule, 
the longer the time required for this realignment, thus it resolves the large DNA 
molecules to migrate according to their size. 
8. DNA extraction using phenol / chloroform 
The DNA of interest was cut out from low melting point agarose and melted in 200 μl 
TE buffer at 80˚C for 10 minutes. Equal volume of phenol (200 μl + the volume of 
the melted agarose) was added to the melted agarose solution, and the mixture was 
spun at maximum speed (14, 000 rpm) in a benchtop Eppendorf centrifuge for 3-4 
minutes. Then the supernatant aqueous layer was transferred to a clean tube and ½ 
volume of phenol and ½ volume of chloroform was added. The mixture was spun at 
maximum speed for 2-3 minutes and the supernatant aqueous layer was transferred to 
a clean tube. DNAs were precipitated by 10% sodium acetate pH 5.5, 1 μl glycogen, 
2-3 volume absolute ethanol. The DNA pellet was dissolved in 10 μl distilled H2O. 
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9. Ligation reaction 
A typical ligation reaction contained 0.1 μg vector (pET-28b (+) or pHβAPr-1) 
linearized by corresponding restriction enzymes, 40 ng PCR insert digested by 
corresponding restriction enzymes, 2.5 units T4 DNA ligase (Promega, USA) and 1 x 
reaction buffer supplied by the manufacturer. Ligation was carried out in a final 
volume of 10 μl at 16˚C for 16 h. 
10. PCR screening 
Inserts in the selected colonies were detected via direct PCR screening. A pair of 
Actin primers (Actin forward primer: 5’ACT TCG GCT CAC AGC GCG3’; Actin 
reverse primer: 5’TCA CTG CAT TCT AGT TGT GG3’) was used for screening 
plasmid pHβAPr with insert N70 / 3 x NLS / Flag-tag or N70/NES/Flag-tag. A pair of 
pET-28b (+) sequencing primers (primer for forward sequencing: 5’TAA TAC GAC 
TCA CTA TAG G3’; primer for reverse sequencing: 5’GCT AGT TAT TGC TCA 
GCG GT3’) was used for screening plasmid pET-28b (+) with insert N70 or 
Ube4b/Nmnat (WldS gene). A pinhead quantity of each putative clone was inoculated 
into a reaction mixture comprising 0.5 μM of each primer, 0.25 mM dNTPs, 0.03 
units / μl of Taq DNA polymerase (Gibco-BRL, USA) and 1 x PCR buffer. PCR was 
carried out as following condition: 1 cycle of denaturation at 94˚C for 2 minutes; 30 
cycles of (denaturation at 94˚C for 45 seconds; annealing at 55˚C for 1 minute; 
extension at 72˚C for 1 minute); and a final cycle of extension at 72˚C for 10 minutes. 
Colonies that contained the inserts were identified and were prepared for sequencing. 
11. Optimization of conditions for the expression of N70 or full length chimeric 
protein (WldS) 
Optimization of conditions for the expression of N70 and full-length chimeric protein 
was performed using small-scale cultures. An overnight culture of the clone of 
interest was made in 1 ml LB containing kanamycin. The next day, a 1:50 dilution of 
the overnight culture was made in 10 ml of fresh media. Three flasks of the culture 
were prepared and incubated at 37˚C, with shaking, until OD600=0.5, 0.8 and 1.0, 
respectively. The cultures were then induced with 1mM IPTG and examined for the 
production of the ~ 8 kDa N70 or ~ 43 kDa WldS recombinant protein after 0h, 1h, 2h, 
3h, 4h of induction with 1mM IPTG. 2-ml aliquots of the cultures were pelleted and 
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lysed using 80 μl lysis buffer (8 M urea; 0.1 M NaH2PO4; 0.01 M Tris×Cl, pH 8.0). 
The pellet and supernatant fractions of the lysate were analyzed on 4% stacking / 15% 
resolving SDS-PAGE for N70 and 4% stacking / 10% resolving SDS-PAGE for full-
length chimeric protein. According to recombinant protein expression level, protein 
expression condition with 1mM IPTG induction for 3h at OD600=0.8 was chosen.  
12. Western blotting 
Western blotting (Towbin et al, 1979) is a technique for detecting specific proteins 
after electrophoretic separation by transferring from the gel to a more manageable 
solid phase support, as in Southern blotting DNA: electrophoretically separated 
protein components are transferred from a SDS-PAGE gel to a solid support 
(nitrocellulose filters) and probed with reagents (antibodies) that are specific for 
antigenic epitopes displayed by the target protein. The bound antibody is detected by 
one of several secondary immunological reagents (125I-labeled protein A or anti-
immunoglobulin, or anti-immunoglobulin or protein A coupled to horseradish 
peroxidase or alkaline phosphatase). As little as 1-5 ng of an average-sized protein 
can be detected by western blotting.   
Semi-dry transfer: 12 pieces of filter paper and a piece of nitrocellulose membrane 
(7.5 cm x 6.5 cm) were soaked in semi-dry transfer buffer (25 mM Tris; 192 mM 
Gycin; 20% methanol). 6 sheets of filter paper were placed on the anode (positively 
charged), followed by the membranes, the gel and finally another 6 sheets of filter 
paper on the cathode (negatively charged). It is important to carefully avoid air 
bubbles during the procedure. Electrotransblotting was carried out at a constant 
voltage of 15 V for 45 minutes. 
13. Buffers for SDS-polyacrylamide gel electrophoresis 
3 x SDS-sample buffer: 150 mM Tris×HCl (pH 6.8); 300 mM DTT; 6% SDS; 0.25% 
Bromphenolblue; 30% Glycerol. 
Separating gel: 
1) 8%: Protogel (30% (w/v) Acrylamide: 0.8% (w/v) Bis-Acrylamide Stock Solution 
(37.5:1)(National diagnostics, USA), 2.67 ml; 1.5 M Tris×HCl, pH 8.8, 2.5 ml; 
10% SDS, 0.1ml; deionized H2O, 4.62 ml. 
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2) 10%: Protogel (30% (w/v) Acrylamide: 0.8% (w/v) Bis-Acrylamide Stock 
Solution (37.5:1)(National diagnostics, USA), 3.33 ml; 1.5 M Tris×HCl, pH 8.8, 
2.5 ml; 10% SDS, 0.1ml; deionized H2O, 3.96 ml. 
3) 12%: Protogel (30% (w/v) Acrylamide: 0.8% (w/v) Bis-Acrylamide Stock 
Solution (37.5:1)(National diagnostics, USA), 4.00 ml; 1.5 M Tris×HCl, pH 8.8, 
2.5 ml; 10% SDS, 0.1ml; deionized H2O, 3.29 ml. 
4) 15%: Protogel (30% (w/v) Acrylamide: 0.8% (w/v) Bis-Acrylamide Stock 
Solution (37.5:1)(National diagnostics, USA), 5.00 ml; 1.5 M Tris×HCl, pH 8.8, 
2.5 ml; 10% SDS, 0.1ml; deionized H2O, 2.29 ml. 
100 ml Ammonium Persulfate (Sigma, Germany) and 10 ml TEMED (Sigma, 
Germany) were added to each solution above and mixed.  
Stacking gel 4%: Protogel (30% (w/v) Acrylamide: 0.8% (w/v) Bis-Acrylamide Stock 
Solution (37.5:1)(National diagnostics, USA), 1.3 ml; ProtoGel stacking buffer (0.375 
M Tris×HCl, pH6.8; 0.1% SDS), 2.5 ml; Deionized H2O, 6.1 ml; 100 ml Ammonium 
Persulfate (Sigma, USA) and 10 ml TEMED (Sigma, USA).  
SDS-running buffer (10 x): 0.25 M Tris; 1.92 M Glycine; 1% SDS; pH 8.3. 
Molecular standards is Precision Plus Protein standards (Bio-Rad, Germany): ten 
protein bands of 10 kD, 15 kD, 20 kD, 25 kD, 37 kD, 50 kD, 75 kD, 100 kD, 150 kD 
and 250 kD are all recombinant proteins. Three reference bands are indicated in bold. 
Coomassie Blue staining solution: methanol, 45% (v/v) (Carl-Roth, Germany); 
distilled H2O, 45% (v/v) (Carl-Roth, Germany); glacial acetic acid, 10% (v/v) (Carl-
Roth, Germany); Coomassie Blue, 0.25% (w/v) (Merck, Germany). 
Destaining solution I: methanol, 50% (v/v); glacial acetic acid, 10% (v/v); distilled 
H2O, 40% (v/v). 
Destaining solution II: methanol, 5% (v/v); glacial acetic acid, 7% (v/v); distilled 
H2O, 88% (v/v).  
The sample (10 ml) was added to 5 ml of 3 x loading buffer and heated at 95°C for 5 
minutes prior to application. Electrophoresis was carried out at a constant voltage of 
100 V for about 2 hours. The gel was fixed and stained by placing the gel in 
Coomassie blue staining solution for 1 h with shaking, destained in a solution I for 1h, 
and then in a solution II until a clear background was obtained.    
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3.1 Introduction 
The slow Wallerian degeneration mouse, C57BL/WldS, carries a dominant mutation that 
delays Wallerian degeneration in the distal stump of an injured axon. The protective gene 
(Ube4b/Nmnat) has been identified and also found to protect axons from the neurotoxin 
vincristine in vitro (Wang et al, 2001; Mack et al, 2001). Therefore, it is important to 
determine whether it has a widespread application to protect axons in neurological 
diseases, such as myelin related peripheral neuropathy, motoneuron disease etc. In 
principle, this can be done by crossing WldS to mouse model of neurological disorders, 
such as P0-/- mice (a mouse model of myelin-related peripheral neuropathy) and pmn (a 
mouse model of motoneuron disease), but first a method is needed to track the 
inheritance of the neuroprotective WldS allele. Due to the complex nature of the mutation, 
there is no simple method to distinguish WldS homozygotes, heterozygotes and wild-type 
mice. Therefore I carried on the study of finding a suitable genotyping method to track 
WldS triplication.  
 
3.2 Result 
3.2.1 Genotyping methods for the WldS triplication. 
Three methods (PCR, Southern blotting and pulsed field gel eletrophoresis (PFGE) were 
discussed below.  
1) PCR. 
PCR primers Wld F and WldR are located at the proximal and distal ends of the 85 kb 
repeat unit, respectively (Figure 3.1 and Section 2.1.2), and thus amplify a 182 bp 
product from WldS genomic DNA which spans the boundary (Figure 3.2). No such 
product is produced from wild type mice, because the primers are separated by 85 kb and 
oriented in opposite directions.  
2) Southern blotting 
When a probe located close to the end of the repeat unit is used, additional restriction 
fragments are seen in WldS mice. Furthermore, the relative strength of the WldS-specific 
band and the constant band can be used to distinguish homozygotes from heterozygotes. 
Probe G11 which is located at the proximal boundary (Figure 3.1 and section 2.1.2), 
hybridized to a 6-kb fragment of identical size in C57BL/6J and in C57/WldS, but also to 
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a WldS-specific fragment (5 kb) of altered size and with an increased intensity (Figure 
3.3). The Wlds-specific band (5 kb) is always stronger than the constant band (6 kb) in 
homozygotes, however the two bands are almost the same intensity as each other in 
heterozygotes. This is because on the Wlds chromosome there are two copies of the Wlds-
specific junction fragments and one normal fragment. Therefore Wlds homozygotes have 
four copies of the Wlds-specific fragments and two of the normal fragment. In 
heterozygotes, however, the fragments are present in equal copy numbers: two junction 
fragments on the Wlds chromosome, plus one copy of the normal fragment on each 
chromosome 4. Since small fragments can blot more efficiently than bigger ones in 
Southern blotting, the constant band looks a slightly less intense in the heterozygotes 
when using an EcoRV where the constant band (6 kb) is slightly bigger than the Wlds-
specific band (5 kb).  
3) Pulsed field gel electrophoresis (PFGE) 
Using rare cutter restriction enzymes that do not cut within the repeat unit, it is possible 
to detect directly the 170 kb insertion corresponding to the 85 kb triplication in Wlds. Any 
single-copy probe within the repeat unit can be used, including GS11 (see Figure 3.1). In 
the experiment shown in Figure 3.4, a different probe (probe 2, see section 2.1.2) was 
used. The probe detects a single NotI fragment of approximately 220 kb in C57BL/6J and 
a single fragment increasing in size to approximately 390 kb in C57BL/Wlds (Figure 3.1 
and Figure 3.4). In WldS heterozygotes, both fragments (220 kb and 390 kb) are detected. 
3.2.2 The application of genotyping methods to track the WldS triplication 
Since the axonal protective gene, the Ube4b/Nmnat chimeric gene was identified within 
the tandem triplication in WldS, determination of WldS genotype could facilitate the 
investigation in the possible role of WldS preventing axon degeneration in diverse 
pathologies and its effect on the symptoms. This could be done by crossing WldS with 
neurodegenerative mutants in which axonal degeneration plays a primary or secondary 
role.  
So far, these genotyping methods (Southern blotting and PFGE) have been applied to 
track WldS inheritance in following experiments:  (1) is an extensive project reported in 
this thesis (chapter 5), (2) and (3) are collaborative projects for which I carried out the 
genotyping (2) or trained investigators from other laboratories (3), (4)-(7) are other 
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ongoing projects within our laboratory or collaborations and (8) has widespread 
applications in many laboratories and animal breeding companies. 
1) Crossing recessive mutant gracile axonal dystrophy (gad) with WldS. To 
investigate whether WldS could prevent axon loss in the gracile tract of gad and 
then further alleviate the phenotype of gad, three groups of offspring are chosen 
by intercrossing double heterozygotes gad+/-/Wld+/S: gad/Wld+/+, gad/Wld+/S, and 
gad/WldS/S. The Wld genotype is confirmed by PFGE on postmortem tissue 
(spleen). The results in detail shown in chapter 5. 
2) Crossing mouse model (P0-/- mouse) of myelin-related peripheral neuropathy with 
WldS.  
One of the major problems of myelin-related disorders, such as multiple sclerosis 
and demyelinating neuropathies, is the progressive loss of the axons that leads to 
irreversible symptoms and permanent disability (Trapp et al, 1998; Korneck et al, 
2000; Martini, 2001). Mice deficient in the peripheral myelin component P0 
mimic severe forms of inherited peripheral neuropathies in humans, with 
defective myelin formation and consequent axonal loss. It is presently not known 
how abnormal myelin or demyelination leads to axonal destruction.  
To investigate whether the robust myelin-related axonal loss in P0-deficient 
mutants follows a similar mechanism to that of Wallerian degeneration and 
whether WldS could rescue the myelin-related axonal loss in such mutant, our 
collaborators in Würzburg crossed P0-deificient mice with C57BL/WldS. Five 
groups of mice were chosen for analysis: P0+/+/WldS-homozygotes (control), 
P0+/+/WT (control), and P0-/-/Wld+/+, P0-/-/WldS/S, P0-/-/WldS/+. Genotyping WldS 
triplication in these mice were conducted in our lab using the shipped and frozen 
spleens, and in total I have genotyped 19 spleens from P0-/-/Wld+/+, 32 from P0-/-
/WldS/+ and 24 from P0-/-/WldS/S. Our collaborators found that in the double 
mutants (P0-/-/WldS/+ and P0-/-/WldS/S), the robust myelin-related axonal loss in 
plantar nerves is reduced ~40% at 6 weeks age and ~30% at 3 months of age. 
Such rescue effect is also present in median nerve, showing ~25% reduction in 
axonal loss at 3 months age (Figure 3.5). Further, they found the rescued and 
morphologically normal axons are functionally intact and active in the 3-month-
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old double mutants. The amplitude of compound muscle action potentials were 
reduced ~50% less in P0-/-/WldS/S than in P0-/-/Wld+/+ (Figure 3.6a). The result of 
retrograde transport of Fluorogold and counting of the corresponding spinal 
motoneurons further backs up the survival of preserved axons and indicates that 
some of the rescued axons are motor axons, which are mainly responsible for the 
disability in Charcot Marie Tooth Disease Type 1: the number of retrogradely 
labeled motoneurons (171±18) in P0-/-/WldS-homo/hetero comparing to (136±21) 
in P0-/- mice and age-matched wild-type mice (177 ± 26), showing 100% 
preservation at 3 months age (Figure 3.6b). In addition to that, the result of the 
muscle strength by performing quantitative grip strength analysis shows 
significant more strength in P0-/-/WldS/S than P0-/- mice at 3 months age (Figure 
3.7). Such rescue effect does not exist in 6-months-old double mutants compared 
to single mutant mice (P0-/-). To investigate whether such loss of axonal 
protection in older double mutants is caused by any decrease in WldS expression, I 
examined the expression level of WldS protein in spinal cord or dorsal root 
ganglia between 6-week-old and 6-month-old double mutants (P0-/-/WldS/S) by 
western blot using rabbit polyclonal anti-Wld 18 antibody (detail in Figure 1.3b). 
There is not a decrease of WldS protein level in older mutants (Figure 3.8).  
The results indicate that myelin-related axonal loss is a process having some 
features in common with Wallerian degeneration, and introducing the WldS gene 
partially rescues axonal loss in mice model of peripheral neuropathy.  This, and 
pmn (below) were the first examples of axon rescue in chronic disease by the 
WldS gene. 
3) Crossing recessive mutant pmn/pmn (progressive motor neuronopathy) with WldS 
Apoptosis is a hallmark of motoneuron diseases such as amyotrophic lateral 
sclerosis (ALS) and spinal muscular atrophy (SMA). In a widely used mouse 
model of motoneuron disease (pmn), transgenic expression of the anti-apoptotic 
bcl-2 gene or treatment with glial cell-derived neurotrophic factor prevents the 
apoptosis of the motoneuron soma; however they were unable to affect the life 
span of the animals (Sagot et al, 1995; Sagot et al, 1996). To determine whether 
WldS could rescue the pmn phenotype, Ann Kato’s lab in Geneva crossed the 
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WldS with pmn mice and the PFG genotyping method helped them to confirm 
WldS genotype (hetero or homo) from wild type mice. In the crossing mice 
(pmn/pmn with WldS-homozygous or heterozygous), WldS attenuates symptoms, 
extends life span, prevents axon degeneration, rescues motoneuron number and 
size, and delays retrograde transport deficits in pmn/pmn mice (Ferri et al, 2003).  
4) Crossing Vegfaδ/δ mice with WldS 
Hypoxia stimulates angiogenesis through the binding of hypoxia-induced factors 
to the hypoxia-response element in the vascular endothelial growth factor (Vegf) 
promoter. VEGF is essential in the formation of new blood vessels (angiogenesis). 
Deletion of the hypoxia-response element in the Vegf promoter reduces hypoxic 
Vegf expression in the spinal cord and caused adult-onset progressive motor 
neuron degeneration, reminiscent of amyotrophic lateral sclerosis. To investigate 
whether axonal-protective protein WldS could play a protective role in mice 
homozygous for the deletion of the hypoxia-response element (Vegfaδ/δ mice), our 
group is crossing WldS with Vegfaδ/δ mice, and double mutants (Vegfaδ/δ/WldS-
heterozygous or homozygous, Vegfδ/δ/Wld+/+) will be selected for behavioral and 
pathological analysis. Southern blotting and PFGE will be applied to track the 
WldS inheritance in those mice. This project is carried out by Dr. Robert Adalbert, 
who I have trained in the PFG technique. 
5) Crossing SOD1 with WldS 
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease 
involving upper and lower motoneurons. Approximately 15% of the total number 
of ALS cases are familial (FALS), and of these, ~20% are attributable to point 
mutations in cytosolic Cu/Zn superoxide dismutase (SOD1) (Deng et al, 1993; 
Pardo et al, 1995). Transgenic mice expressing high level of one of three FALS-
associated SOD1 mutants (G93A) under the control of a human SOD1 minigene 
(hMg) were crossed with WldS to investigate whether WldS could rescue the axon 
loss in this mice model of late-onset ALS-like motoneuron disease. Such 
experiments are carried on in our collaborator’s lab in US (Jonathan Glass). Again, 
our genotyping method (PFGE) will be applied to distinguish the WldS from 
Wld+/+ and WldS-heterozygous from WldS-homozygous.  
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6) Crossing Smn mutants with WldS 
Mutations of survival of the motor neuron gene (SMN1) are responsible for spinal 
muscular atrophy (SMA), a common genetic cause of death in childhood. Mice 
carrying a homozygous deletion of Smn exon 7 directed to neurons (Smn mutant 
mice) were generated in a collaborator’s lab in France (Judith Melki). These 
mutant mice display a dramatic and progressive loss of motor axons involving 
both proximal and terminal regions, with aberrant cytoskeletal organization of 
synaptic terminal, thus Smn mutant mice represent a valuable model of SMA. To 
test whether WldS could rescue such axonal loss in Smn mutant mice, these 
mutants were crossed with WldS and Southern blotting was applied to genotype 
WldS. In this experiment it is only necessary to identify WldS heterozygotes so the 
EcoRV genotyping method is used.   
7) Generation of CFP/WldS/S double homozygotes. 
To facilitate examining the nerve terminals (such as axons and synapses) and 
NMJs (neuronal muscular junctions) in WldS and thus give us the hints of the 
mechanism of Wallerian degeneration, Richard Ribchester’s lab in Edinburgh 
generated CFP/WldS/S double homozygotes mice. Again, genotyping method 
(PFGE) was applied to confirm WldS genotype in our lab, which was done by 
Arzu Celik, following training from myself.  
8) Confirmation of mouse imports and breeding colony maintenance.   
Whenever the WldS mice were shipped to the lab from different sources, either 
from collaborators’ lab or from Harlan Orlac, UK, we need to use genotyping 
method to confirm the presence of WldS in the genome. For the living mice, we 
used Southern blotting with the genomic extraction from mice tail tips, and for the 
postmortem samples, we use PFGE with spleen as a starting material (methods 
see 2.1.1 and 2.1.2). To maintain the WldS breeding colony, the same strategy also 
can be applied to either living or postmortem samples. 
 
3.3 Discussion 
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We describe methods to determine the genotype of Wlds using PCR, Southern-blotting or 
pulsed field gel electrophoresis (PFGE). PFGE is the only qualitative method to 
distinguish homozygotes from heterozygotes. 
In the PCR assay, there is a Wlds-specific product but given the nature of the mutation, it 
is not possible to design a PCR that yields a wild-type specific product. Therefore it is 
difficult to distinguish homozygotes from heterozygotes, or wild-type from false negative. 
The Southern blotting assay resolves this false negative problem because the constant 
wild-type band acts as an internal control. It also resolves the homo/heterozygotes 
problem to some extent because this can be determined from the relative strength of 
Wlds-specific band and the constant band. However, we do not recommend this 
quantitative approach for genotyping for experiments where it is important to distinguish 
homozygotes from heterozygotes, as the result could be affected by artifacts such as 
Southern blotting efficiency and partial digestion. The pulsed field gel electrophoresis 
method is based on altered fragment size rather than altered fragment intensity and is 
therefore more reliable. However since spleen is the usual starting material in order to 
yield enough high molecular weight DNA from a soft tissue, this determination will 
usually have to be made post-mortem. In cases where the mouse is perfused, it is clearly 
important to remove the spleen or a fragment of it before fixation. 
Determination of genotype of Wlds has become more important after the identification of 
the protective gene, the Ube4b/Nmnat chimeric gene within tandem triplication in Wlds 
(Mack et al, 2001; Conforti et al, 2000). The possibility of Wlds preventing axon 
degeneration in diverse pathologies and its effect on the symptoms should now be 
actively investigated by crossing Wlds with neurodegenerative mutants in which axon 
degeneration plays a primary or early secondary role. By reporting several genotyping 
protocols and discussing their relative merits we make it possible to follow inheritance of 
the Wlds chromosome in such studies. Genotyping can now also be used to confirm the 
Wlds strain when breeding or shipping mice. 
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Figure 3.1 Tandem triplication schematic diagram model. Probe GS11 was used in 
Southern blotting. Probe 2 was used in pulsed-field gel electrophoresis. The restriction 
cutting cites for NotI (N) and EcoRV (E) were indicated. WldF and WldR were primers 
used in PCR. 
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Figure 3.1 
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Figure 3.2 PCR showing the detection of a 182 bp Wlds-specific band in WldS homo- and 
heterozygotes, but not in C57BL/6J. 
 
 
 
 
Figure 3.3 Southern blotting showing the detection of 6 kb constant band in wild type 
(C57 BL/6J) and Wlds, plus a 5 kb Wlds-specific band. Probe used for Southern blotting is 
GS11 (see the localization of probe in Figure 3.1).  Lane 1-2: C57BL/6J samples; lane 3-
4: WldS heterozygous; lane 5-6: WldS homozygous. 
 
 
 
 
Figure 3.4 Pulsed-field gel analysis of C57BL/Wlds and C57BL/6J genomic DNA 
digested with NotI. Probe 2 was used in this assay and located centrally within the repeat 
unit (see the localization of probe in Figure 3.1).  
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Figure 3.2                     
 
 
 
Figure 3.3 
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Figure 3.5 Schematic representation of numbers of axons in plantar (A) and median (B) 
nerves of 3-month-old P0+/+ and P0-/- mice with or without the WldS mutation.  
Note that the WldS mutation has no influence on axon numbers in P0+/+ genotypes. 
However, in P0-/- mice, loss of axons is significantly reduced in mice carrying the WldS 
mutation. ***p<0.0001; **p<0.002; *p<0.05. n, number of individuals of the respective 
genotype investigated. hom, Homozygous; het, heterozygous. 
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Figure 3.5 
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Figure 3.6a Schematic representation of amplitudes of compound action potentials from 
small foot muscles of 3-month-old P0+/+ and P0-/- mice with and without the WldS 
mutation on distal stimulation of sciatic nerves. Note that the WldS mutation has no 
influence on amplitudes in P0+/+ genotypes. Amplitudes are markedly reduced in the 
absence of P0 (P0-/-), but reduction is less pronounced in the myelin mutants carrying the 
homozygous WldS mutation. Amplitudes from P0-/- mice heterozygous for the WldS 
mutation show a slight trend toward higher values compared with P0-/- single mutants. 
***p<0.0001 and *p<0.05. n, Number of individuals of the respective genotype 
investigated. 
 
 
 
 
 
 
Figure 3.6b Schematic representation of retrogradely labeled spinal motoneurons of 3-
month-old mice using Fluorogold. P0-/-/WT mice show a significantly lower number of 
back-labeled spinal (lumbosacral) motoneurons than P0+/+/WT mice (*p<0.05). In 3-
month-old P0-/-/WldS double mutants, however, the number of labeled motoneurons is as 
high as in P0+/+ mice, indicating a significant preservation of P0-/- motor axons on WldS 
expression. n, Number of individuals of the respective genotype investigated. WT, wild 
type; hom, homozygous; het, heterozygous. 
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Figure 3.6 
m
V
0
2
4
6
8
10
12
14
16
P0++/WLDs-hom
P0++/WT
P0--/WT
P0--/WLDs-hom
P0--/WLDs-het
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=4 n=5 n=6 n=10 n=8 
*** 
* 
a 
 69
Figure 3.6 
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Figure 3.7 Schematic representation of muscle strength (grip test of forelimb) of P0+/+ and 
P0-/- mice (3 months of age) with and without the WldS mutation. The WldS mutation has 
no influence on muscle strength in P0+/+ genotypes. Muscle strength is strongly reduced 
in P0-/-/WT mice, but reduction is less pronounced in P0-/-/WldS-homozygous mutants. 
Muscle strength of P0-/- mice carrying a heterozygous WldS mutation show a small, non-
significant trend toward higher values compared with P0-/- single mutants. ***p<0.0005; 
*p<0.05. n, Number of individuals of the respective genotype investigated. WT, wild 
type; hom, homozygous; het, heterozygous. 
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Figure 3.7 
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Figure 3.8 Western blot analysis of young versus old P0-/-/WldS double mutants. Lumbar 
spinal cord (SPC) and lumbar (L4 – L5) dorsal root ganglia (DRG) homogenates of 6-
week-old versus 6-month-old P0-/-/WldS double mutants show a similar WldS expression 
(WldS). Transgenic (Tg WldS) WldS and wild-type lanes show that the observed band is 
specific for WldS mice. ß-Tubulin (ß-Tub) expression in spinal cord and dorsal root 
ganglia homogenates are shown as controls. Hom, Homozygous.  
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Figure 3.8 Western blot analysis of young versus old P0-/-/WldS double mutants. 
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CHAPTER 4 
 
 
THE 85-kb TRIPLICATION IN C57BL/WldS IS STABLY 
INHERITED 
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4.1 Introduction 
Two duplication cases have been identified before in mice bred in the Department of 
Physiology, University of Oxford in 1996 and 1997 (Coleman et al, 1998)(Figure 4.1b) 
and the tandem triplication in the WldS mouse is very likely to have developed from 
duplication by homologous, but unequal, crossing-over between tandem head-to-tail 
repeated DNA sequences (Figure 4.2)(Jeffreys et al, 1988; Tartof, 1988) (see details in 
section 1.3). The duplication-triplication instability could have been a single event, or 
there could be a dynamic equilibrium between two repeats and three repeats, especially 
considering the large homologous regions available for recombination, and thus reversion. 
In addition diverged breeding colonies of WldS have been suggested to have different 
phenotypic properties (Crawford et al, 1995) and one possible explanation proposes that 
the mutation is not the same. Furthermore, given the dose-dependence of the WldS 
phenotype (Mack et al, 2001), it is important to determine whether all WldS mice carry 
the same gene dosage or whether they are highly variable. Somatic reversion would also 
have the possibility to explain the observed reduction in phenotype with age (Perry et al, 
1992), so it is important to study the mutation in old mice as well. To answer these 
questions, I carried out a genomic instability study in WldS mouse using pulsed field gel 
electrophoresis assay (Mi et al, 2002). Chromosomes from three diverged breeding 
colonies were examined, together with chromosomes from aged mice. 
 
4.2 Result 
4.2.1 Sources of WldS tissues.  
C57BL/WldS spleens were obtained from three diverged breeding colonies (Table 4.1): 
(1) Harlan-Olac, Bicester, UK, which is the parent colony. Some mice were F1 or F2 
from breeding stock derived from Harlan-Olac. 
(2) Johns Hopkins Laboratories. This breeding colony was established from the 
Harlan-Olac colony in 1989 using four breeding pairs and has been maintained 
separately since then. 
(3) Biosonda, Santiago, Chile. This breeding colony was established from the Harlan-
Olac colony in 1996 using 4 males and 12 females and maintained separately. 
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Other breeding colonies, e.g., those originally set up at Edinburg, UK, and Kingston, 
Canada appeared to have been discontinued. This was also the case for that at the 
Department of Physiology, Oxford, UK, where the duplication allele was previously 
observed. Four mice directly from Harlan-Olac were aged to 12 months before 
genotyping their spleens and three were aged to 15 months. Spleens were stored at -80˚C 
until use. 
4.2.2 Stable inheritance of an 85-kb triplication in C57BL/WldS. 
A total of 132 WldS chromosomes from homozygous and heterozygous WldS mice no 
more than two generations beyond those, originally obtained from Harlan-Olac were 
examined using pulsed field gel electrophoresis (see details in section 3.2.1). The original 
duplication result was confirmed but there was no clear sign of a duplication allele in the 
recently obtained WldS mice (Figure 4.1). Similarly, no quadruplications were observed, 
which could be the predicted reciprocal product of partial reversion. Although we cannot 
rule out a low rate of somatic reversion in the spleen due to the detection limit of pulsed 
field gel assay, results from these 132 WldS chromosomes strongly indicate that 
occurrence of the duplication allele is a very rare event (Table 4.1). 
In order to investigate whether somatic reversion might occur in older mice, we studied 
an additional 6 chromosomes of 15 month old mice and 8 chromosomes of 12 month old 
mice. Again, only the triplication allele was observed (Figure 4.1a; Table 4.1), indicating 
that somatic reversion in spleen is unlikely.   
Although these data indicate that the triplication / duplication rearrangement is very rare, 
it is still important to know the genotype of other WldS breeding colonies, in order to 
facilitate the comparison of results from different breeding colonies. Therefore, in order 
to test whether the duplication allele might exist in those colonies, we genotyped mice 
from current breeding colonies that are diverged from Harlan-Olac. 16 WldS 
chromosomes of mice from the Johns Hopkins colony and 18 WldS chromosomes of mice 
from Biosonda, Chile showed only triplication (Figure 4.1; Table 4.1).   
In total 180 chromosomes of WldS from 3 divergent breeding colonies have been 
examined and all found to carry the triplication.  Thus the triplication mutation is stable 
during both mitosis and meiosis, and the previously observed duplication is likely to have 
been surviving alleles of the original mutation rather than a partial reversion. The 
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triplication has now been shown to be the causative mutation, acting through an 
Ube4b/Nmnat chimeric gene (Mack et al, 2001), indicating the possibility of Wld 
preventing axon degeneration in diverse pathologies and altering the symptoms. The fact 
that triplication is stable rules out instability as a source of phenotypic variation. Thus 
this result is essential for accurate interpretation of studies the effect of WldS on 
neurodegenerative phenotypes. It is necessary to track WldS inheritance (Wld+/+, or Wld+/S, 
or WldS/S) when crossing WldS with mice model of neurodegenerative diseases, such as 
P0-/- and gad (see details in section 3.2.2), thus the drawing conclusion of stable 
inheritance of triplication in WldS will facilitate the evaluation of such studies. 
Conclusions: all current WldS is triplication. Any reversion rate is extremely low; much 
lower than comparably-sized mammalian duplications such as pink-eyed unstable 
mutation (Gondo et al, 1993).  
 
4.3 Discussion 
Results from 180 WldS chromosomes of mice from 3 diverged breeding colonies indicate 
that the rate of occurrence of duplication in WldS mice is very low. Thus, we conclude 
that the WldS triplication is stable under normal conditions and that it is the predominant, 
and possibly exclusive, allele in the current WldS breeding colonies.  
WldS is thus more stable than some other rearrangements of comparable size in mammals, 
such as the pink-eyed unstable mutation (pun). It would be interesting to know whether 
mutagenic treatment such as radioactivity or carcinogens would make it less stable, as it 
is the case with pink-eyed (Schiestl et al, 1994; Schiestl et al, 1997). 
We did not find any duplication in aged mice (1 year or more) also, which suggests that 
the “different mutation” theory (e.g., triplication reverts to duplication) does not underlie 
observed differences in age effect (Crawford et al, 1995) and further supports stability 
during mitosis as well as during meiosis. This is further supported by the observation that 
there are no age-dependent changes in expression level of the WldS protein (Gillingwater 
et al, 2002; Samsam et al, 2003). While we cannot rule out other genetic explanations, 
the observed difference in age-effect is more likely to be explained by different 
experimental approaches. 
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Results from 3 breeding colonies do not show any duplication, suggesting that the parent 
colony (Harlan-Olac, UK) must have been predominantly triplication as far back as 1989. 
The alternative explanation that the triplication arose and became fixed independently in 
three different breeding colonies seems unlikely. The duplication alleles identified in 
mice bred in the Department of Physiology, University of Oxford in 1996 and 1997 were 
probably persisting original duplication mutations that are now extinct. However, we 
cannot rule out the possibility that a single rare meiotic partial reversion occurred in this 
subline. Somatic instability occurring independently in the two respective mice, however, 
now seems extremely unlikely, given the far greater number of mice studied in the 
present paper without signs of somatic instability.    
Finally, the fact that the triplication is stable rules out instability as a source of 
phenotypic variation. It is important to know this for studies addressing the effect of WldS 
on neurodegenerative phenotype. 
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Table 4.1 Triplication results of WldS chromosomes examined by PFGE 
Results  Mice origin (source 
of breeding colony) 
WldS 
chromosomes 
No. 
Triplications  
No. 
Duplications 
No. 
1a Harlan-Olac, U.K. 132 132 0 
1b Harlan-Olac, U.K. 
12 months old 
8 8 0 
1c Harlan-Olac, U.K. 
15 months old 
6 6 0 
2 Johns Hopkins. USA 
(diverged from 
Harlan-Olac) 
16 16 0 
3 Biosonda, Chile 
(diverged from 
Harlan-Olac) 
18 18 0 
Total  180 180 0 
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Figure 4.1a Pulsed field gel analysis of C57BL/WldS chromosomes from 3 diverged 
breeding colonies. Probe located within triplication detected a single fragment of 
approximately 390 kb in C57BL/WldS, a fragment of 305 kb in duplication allele and a 
fragment of 220 kb in C57BL/6J wild type mouse.  a) three samples (1-3) from Harlan-
Olac, Bicester, UK. b) three samples (4-6) from Johns Hopkins Laboratories. c) three 
samples (7-9) from Biosonda, Santiago, Chile. d) three samples (10-12) from older mice 
(12 months). e) one sample from C57BL/6J and one from the Department of Physiology, 
Oxford, UK, where the duplication allele was previously observed. 
 
 
 
 
 
 
Figure 4.1b Identification of 170- kb (triplication) and 85-kb (duplication) insertions in 
C57BL/Wlds from breeding colonies in Department of Physiology, Oxford (Coleman et 
al, 1998). WldA is representative of five of seven DNAs analyzed, whereas WldC and 
WldD were unique. Probe located centrally within the repeat unit. 1: WldA; 2: C57BL/6J;  
3: WldC; 4: C57BL/6J; 5: WldD. 
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Figure 4.1a 
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Figure 4.2 Unequal crossing-over between tandem head-to-tail repeated DNA sequences 
produces one copy and tandem triplication respectively.  
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Figure 4.2  
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CHAPTER 5 
 
 
THE WldS MUTATION REDUCES AXONAL SPHEROID 
PATHOLOGY IN GRACILE AXONAL DYSTROPHY (gad) MICE 
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5.1 Introduction 
The gracile axonal dystrophy (gad) mouse is an autosomal recessive mutant characterized 
by ‘dying-back’ axonal degeneration and formation of spheroid bodies primarily in the 
gracile tract (Yamazaki et al, 1988; Saigoh et al, 1999).  The gracile tract consists of 
thoracic, lumbar and sacral DRG axons that travel up the dorsal column of the spinal cord 
within the gracile fascicle, where they terminate in the medulla oblongata within the 
gracile nucleus. The gad mutation is an in-frame deletion of Uch-l1, and disrupts Uchl1’s 
function in generating free monomeric ubiquitin and thus its essential role in continuing 
the function of the proteasome-ubiquitin system (Saigoh et al, 1999).  
Axonal spheroids morphologically and immunochemically similar to those of gad mice 
also occur widely in CNS neurodegenerative pathology, including myelin disorders 
(Griffiths et al, 1998), tauopathies (Lewis et al, 2000; Probst et al 2000), ALS (Tu et al, 
1996; Oosthuyse et al, 2001; Howland et al, 2002), traumatic brain injury (Cheng and 
Povlishock, 1988), Alzheimer’s disease (Brendza et al, 2003), Parkinson’s disease 
(Galvin et al, 1999), Creutzfeldt-Jakob disease (Liberski et al, 1999) and Niemann-Pick 
disease (Bu et al, 2002). They also occur during normal ageing and secondarily in some 
serious illnesses (Sung et al, 1981). In contrast, PNS axons undergo ‘Wallerian-like’ or 
‘dying-back’ degeneration, even in the same disease such as gad in mouse and human 
ALS and Alzheimer’s disease (Miura et al, 1993; Oosthuyse et al, 2001; Lewis et al, 
2000), although swellings occur in some rare PNS disorders (Miike et al, 1986; Bomont 
et al, 2000).  
Spheroids are focal 10-50 mm diameter swellings, filled with disorganized neurofilaments, 
tubules, organelles or multi-lamellar inclusions, mostly in long axons. In ‘dying-back’ 
disorders they predominate in distal axons, appearing further proximal with increasing 
age (Mukoyama et al, 1989; Bu et al, 2002), whereas proximal spheroids occur in spinal 
cord motor neurons of ALS patients and mouse model (transgenic mice carrying a human 
mutant SOD1) (Tu et al, 1996), and spinal cord of transgenic mice overexpression of 
human four-repeat tau with tauopathy (Probst et al, 2000) (Figure 5.9). Most spheroids 
contain neurofilament and amyloid precursor proteins, and sometimes ubiquitin, tau or 
synuclein.  
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The role of axonal spheroids in disease is poorly understood. Although a common axonal 
response to diverse insults, spheroids could arise by disease-specific mechanisms. 
Although manifestations of axon degeneration, they could also contribute, impairing 
axonal transport to and from more distal sites. Distal and proximal spheroids might arise 
by related mechanisms or distal spheroids could originate distinctly as ‘dying back’ 
axonal endbulbs. Why spheroids are rarer in PNS pathology, and whether preventing 
them in CNS preserves axon function is unknown. These questions could be addressed if 
a method to prevent or delay spheroids were available. 
WldS can protect axons from vincristine toxicity in vitro (Wang et al, 2001), and delay 
axon loss and symptom in diverse PNS disorders, such as myelin-related peripheral 
neuropathy (in the P0-/- mouse)(Samsam et al, 2003; section 3.2.2) and progressive motor 
neuronopathy (in the pmn mouse)(Ferri et al, 2003; section 3.2.2) in vivo. Since the gad 
mouse is the first mammalian model of neurodegeneration with a defect in the ubiquitin 
system and with dying-back type degeneration with formation of spheroids as primary 
defect (gracile tract) in CNS, crossing gracile axonal dystrophy (gad) with WldS will 
provide important information on: 1) whether WldS could have an effect on axonal 
spheroids in CNS; 2) whether the mechanism of Wallerian degeneration, dying-back 
axonal degeneration and axonal spheroid pathology are related, which would be crucial to 
the pathogenesis of some neurodegenerative disease characterized with dying-back 
degeneration.  
 
5.2 Result 
5.2.1 WldS can function to protect axons in gad mice 
gad causes axon degeneration through defective ubiquitin metabolism (Osaka et al, in 
press), while WldS protects axons probably through a ubiquitin-related mechanism too, 
such as N-terminal 70 amino acids of Ube4b sequestering of ubiquitination factors by 
protein-protein interactions and ubiqutination within nucleus altering transcription factor 
stability or RNA processing, leading to an axon effect mediated by unknown protein 
(Mack et al, 2001; Coleman and Perry, 2002). In order to test for direct antagonism 
between gad and WldS and to show that WldS delays Wallerian degeneration in the 
presence of gad, we transected sciatic nerves before onset of hindlimb weakness in two 
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gad homozygotes that were heterozygous for WldS.  These mice also carried a YFP-H 
transgene (Feng et al, 2000) to allow a rapid assessment of Wallerian degeneration 
(Beirowski et al, submitted). No degradation of heavy neurofilament protein could be 
detected in distal sciatic nerves five days after nerve lesion (Figure 5.2a) and all YFP-
labeled axons were unfragmented (Figure 5.2b) compared to total fragmentation at 52 
hours in non-WldS mice (Beirowski et al, submitted). The WldS phenotype is highly dose-
dependent (Mack et al, 2001) so the complete preservation of axons for five days in a 
WldS heterozygote convincingly demonstrates that gad does not significantly weaken the 
WldS phenotype.  Thus it is feasible to test the effect of WldS on gad pathology and likely 
that WldS and gad are not directly antagonistic.   
5.2.2 Genotyping of gad and WldS status. 
In the following text, gad+/+, gad+/- and gad-/- refer to wild-type, heterozygous and 
homozygous gad mice respectively. Crossing gad+/- with WldS/S results in exclusively 
Wld+/S, so double heterozygous mice (gad+/-/WldS/+) could be identified by genotyping for 
gad as described below and intercrossed. Before any further behavioral and pathological 
analysis of gad homozygotes amongst the offspring (gad-/-/WldS/S, gad-/-/WldS/+, gad-/-
/Wld+/+), a method is needed to genotype the gad status. 
Genomic DNA extracts from tail tips from 3-4 week-old mice were digested by PvuII at 
37˚C overnight, and run on 1 % TAE gel overnight. DNA on the gel was Southern-
blotted overnight onto Hybond N+ (Amersham) in 0.4 M NaOH. It was then hybridized 
with a 32P labeled 764 bp probe generated by PCR from gad homozygous genomic DNA 
using primers 5’ ATCCAGGCGGCCCATGACTC 3’ and 
5’AGCTGCTTTGCAGAGAGCCA 3’.  The gad mutation is caused by an in-frame 
deletion of exon 7 and exon8 (3.5 kb of genomic DNA) of Uchl1 (Figure 1.4), so a 764 
bp gad-specific probe (Saigoh et al, 1999) could detect 726 bp gad-specific fragment in 
gad homozygote, ~1.6 kb wild type specific fragment in gad wild type, and both 
fragments in gad heterozygote (Figure 5.1). gad+/- /WldS/+ were selected for intercrossing, 
and the resulting gad-/- (with or without WldS) were chosen for further behavioral  and 
pathological analysis. 
The Wld status (Wld+/+, WldS/+ or WldS/S) in gad-/- mice was genotyped postmortem by 
pulsed-field gel electrophoresis (see section 3.2.1).   
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5.2.3 Axonal spheroid pathology is reduced by WldS 
In order to determine the effectiveness of WldS on gad axonal spheroid pathology, I 
counted axonal spheroids in approximately 90 H&E stained 6 µm paraffin sections from 
throughout the gracile nucleus and 30 sections from throughout the cervical spinal cord 
of each 18-week old gad mouse and gad/WldS double homozygote. 50% fewer spheroids 
were found in gracile nucleus of gad/WldS mice than in gad mice (p=0.0004) and 63% 
fewer in cervical gracile fascicle (p=0.0011) (Figure 5.3). These highly significant 
reductions indicate a strong protective effect of WldS that lasts well into late-stage disease. 
Intermediate values were observed in WldS heterozygotes, further supporting the result. 
No spheroids were observed in control animals of this age (data not shown).    
A reduction in the number of axonal spheroids could result theoretically from either 
reduced axon pathology or pathology so extensive that the axons are completely 
destroyed. However, when gad pathology is made worse by crossing with Uch-l3 null 
mice, extensive axon pathology with a significant increase in the number of spheroids 
becomes detectable at more caudal locations in cervical and thoracic gracile fascicle 
when compared with Uch-l1gad single homozygotes  (Kurihara et al, 2001). We did not 
observe this, and WldS homozygotes maintain a rostral-caudal gradient of axonal spheroid 
pathology, suggesting that gad remains a ‘dying-back’ pathology in WldS mice but that its 
progress is delayed. 
5.2.4 Secondary myelin loss and astrocyte activation are reduced by WldS 
To determine the integrity of axon-myelin units in gad/WldS mice, the density of luxol 
fast blue myelin staining was measured in two 6 mm poly-L-lysine coated paraffin 
sections from the gracile nucleus and two sections from the cervical spinal cord of each 
18-week old gad mouse and gad/WldS double homozygote. Further evidence of a reduced 
loss of axon-myelin units in gad/WldS mice came from a significant reduction (p=0.018) 
in secondary myelin loss in cervical gracile fascicle in the same animals (Figure 5.4 a, b, 
c). A similar protective trend in the medulla oblongata did not reach statistical 
significance (p=0.059), probably due to the naturally weaker myelination in this region, 
but WldS clearly did not cause any deterioration so the reduction in axonal spheroid 
numbers (Figure 5.3) must reflect reduced pathology and not wholesale axon loss. It is 
difficult to conduct electrophysiology study in axonal tract of central nerve system, 
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however, as the rescued axons remain myelinated, they potentially retain normal 
conductance properties, at least in these locations. It is unlikely that WldS has any direct 
effect on myelin because expression of WldS in glia does not alter Wallerian degeneration 
(Glass et al, 1993).  Thus reduced myelin loss in gad/WldS mice is likely to reflect the 
maintenance of functional axon-myelin units.     
Increased immunostaining by GFAP has also been reported in gad mice, reflecting 
astrocyte activation in response to axon damage (Yamazaki et al, 1988). We quantified 
this in gad/WldS mice and found it to be significantly reduced (p=0.015) in gracile 
nucleus compared to gad mice (Figure 5.4 d, e, f), with a non-significant trend in the 
same direction in cervical gracile fascicle (p=0.121). Thus, both direct and indirect 
measures of spheroidal axon pathology in the gracile tract are reduced by the WldS gene.  
5.2.5 Behavioral changes due to WldS are complex 
In the absence of any behavioral test to target specifically the gracile tract that contains 
the primary sensory central projections of dorsal root ganglion, we carried out several 
other tests to determine the effect of WldS on the general gad phenotype. No significant 
change was found in splay test or hindlimb clasping (Figure 5.6 and 5.7), but, 
paradoxically, the steady deterioration in Rotarod performance of gad mice was 
anticipated by 5.5 weeks in WldS homozygotes (Figure 5.5) and by 5 weeks in 
heterozygotes (data not shown). The statistical significance was greatest beyond 14 
weeks (p=0.002 at 18 weeks when data for both homo- and heterozygous WldS are 
combined). This may reflect either failure of WldS to preserve motor nerve terminals in 
older mice or the fact that a constant difference becomes proportionately greater as 
performance declines. In parallel to the decline in Rotarod performance, mice began to 
drag their back legs during normal walking (not shown), indicating that progressive 
hindlimb paralysis, rather than any learning, balance or coordination defect underlies the 
poor Rotarod performance. All non-gad mice remained on the Rotarod for 300 seconds 
regardless of the presence of WldS (data not shown).   
5.2.6 gad/WldS motor nerve terminals degenerate extensively by 15 weeks (done by 
collaborators Dr. Thomas Gillingwater and Dr. Richard Ribchester, University of 
Edinburgh) 
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The neuromuscular junction is an additional major site of pathology in gad mice (Miura 
et al, 1993) and having observed that developing hindlimb paralysis is the cause of 
falling from the Rotarod we examined neuromuscular junctions for evidence of altered 
endplate denervation in gad/WldS mice. Extensive denervation was observed in lumbrical 
muscles from 15 week old mice, even in the presence of WldS (Figure 5.8), as 53.5 ± 
11.8% of endplates were at least partially denervated in gad/WldS mice and 32.3 ± 14.8% 
fully denervated (n=4). Thus, the reason why gad/WldS mice do not perform better in 
Rotarod than their gad littermates is likely to be that neuromuscular innervation is the 
limiting factor. However, we found a similar degree of denervation in gad without WldS, 
so the reason for the worse performance of gad/WldS remains unclear. One possibility is 
that delayed clearance of intramuscular nerve branches in WldS mice might delay a 
compensatory sprouting reaction. It remained possible that WldS might protect motor 
nerve terminals at younger ages, particularly as its ability to protect synapses after 
axotomy decreases dramatically with age: with 50%-90% of endplates partially or fully 
occupied after 5 days axotomy in 2-month-old WldS mice and with less than 5% of 
endplates occupied after 3 days axotomy in 7-month-old WldS mice (Gillingwater et al, 
2002). However, at 9 weeks one gad mouse and one gad/WldS mouse showed almost no 
denervation (Figure 5.8 c and d) suggesting that there is little or no time window in which 
both gad and WldS exert their effects on the neuromuscular synapse. Our data differ from 
Miura et al. (1993), who reported extensive denervation at 9 weeks, perhaps because of 
the different staining methods employed or because of different genetic backgrounds of 
the mice. However, our data reveal two important points. First, protection of motor nerve 
terminals by WldS in a disease setting is weaker than its protection of axons, as spheroid 
numbers in gracile tract remained low in mice even three weeks older (Figure 5.3). This 
matches similar observations made in axotomy experiments. Second, the Rotarod 
deficiency in gad mice is more likely to be linked to denervation of neuromuscular 
junctions than to gracile tract pathology.      
 
5.3 Discussion 
WldS protection from axonal spheroids in gad is the first indication that WldS can 
alleviate axon pathology in chronic CNS disease, and indicates that WldS delays a central 
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step of axon pathology. Pathological mechanisms, whether initiated by defective 
ubiquitin metabolism or other degenerative stimuli (Lunn et al, 1989; Wang et al, 2002; 
Samsam et al, 2003; Ferri et al, 2003), converge on a step delayed by WldS (Figure 5.11). 
Divergent pathological manifestations result, namely axonal spheroids in gad, Wallerian 
degeneration in injury models, and dying back axon loss without spheroids in peripheral 
neuropathy and motor neuronopathy. Alternatively, WldS could alter multiple steps of 
axon pathology, but either way an unexpected mechanistic or regulatory relationship is 
revealed between axonal spheroids and Wallerian degeneration. 
It is now essential to determine whether WldS reduces axonal spheroids in other CNS 
diseases, where their occurrence is widespread. The mechanistic relationship between 
proximal spheroids in ALS, dystrophic axons in amyloid plaques and distal spheroids in 
gad can now be studied. The clinical implications of preventing spheroids in ALS, 
Alzheimer's disease, Parkinson’s disease, brain trauma and CNS myelin disorders would 
be considerable, but more immediately, reducing spheroid pathology in animal models 
helps to understand the consequences of spheroid pathology. Further studies should also 
ask whether reducing axonal spheroid formation in gad or elsewhere translates into 
maintenance of axon function. 
gad/WldS mice suffered extensive synapse loss by 15 weeks (Figure 5.8) whereas axon 
pathology was still strongly reduced three weeks later (Figure 5.3). We could not study 
whether gad/WldS synapses were protected in younger mice, where WldS delays synapse 
loss after axotomy (Gillingwater et al, 2002), because consistent synapse pathology 
developed only later, even with gad alone. However, our data do indicate the importance 
of synapse loss for gad symptoms and suggest that synapse pathology contributes to the 
eventual decline in other models protected by WldS (Samsam et al, 2003; Ferri et al, 
2003). The data also support the hypothesis that different mechanisms underlie synaptic 
and axonal degeneration, with WldS affording only limited protection to synapses 
(Gillingwater and Ribchester, 2001; Gillingwater et al, 2002). 
A link between axonal spheroids, 'dying-back', and Wallerian degeneration is supported 
by previous observations. First, axons degenerate in a single disease with spheroids in the 
CNS and without spheroids in the PNS, indicating that CNS spheroid pathology and PNS 
‘dying-back’ are related. In gad mice, this occurs even within the same cell, as gracile 
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tract central projections of lumbar primary sensory neurons have spheroids, while 
peripheral muscle spindles degenerate without swelling (Oda et al, 1992). Similarly, ALS 
in humans (Tu et al, 1996; Takahashi et al, 1997), mice (Tu et al, 1996; Oosthuyse et al, 
2001) and rats (Howland et al, 2002), together with tauopathy in mice (Lewis et al, 2000; 
Probst et al, 2000), all show axonal spheroids in spinal cord and other CNS areas but 
extensive ‘Wallerian-like’ degeneration without spheroids in ventral roots and peripheral 
nerves. Second, ‘dying-back’ axonopathy and Wallerian degeneration are related, as WldS 
delays axon loss in Taxol toxicity (Wang et al, 2002), peripheral neuropathy (Samsam et 
al, 2003) and motor neuronopathy (Ferri et al, 2003). Our studies now complete the 
three-way relationship, with spheroids, 'dying-back' and Wallerian degeneration all 
delayed by a single mutation. 
The striking contrast between the morphology of axonal spheroids and Wallerian 
degeneration makes these findings particularly surprising. However, even injury-induced 
Wallerian degeneration shows different morphology depending on experimental 
circumstances. First, when injured gracile tract axons undergo Wallerian degeneration 
they swell to spheroid-like dimensions quite unlike Wallerian degeneration in the PNS 
(George and Griffin, 1994)(Figure 5.10). Second, crush injury in the PNS causes a 
retrograde degeneration that is clearly distinct from degeneration induced by transection 
(Lunn et al, 1990) but these processes are related because both are delayed by WldS 
(Beirowski et al, unpublished data). Third, WldS nerve terminals degenerate differently 
according to their age, withdrawing gradually from young endplates but degenerating 
synchronously at older junctions (Gillingwater et al, 2002). Thus, differences in 
morphology in this field do not necessarily indicate totally distinct mechanisms. 
It is intriguing how related mechanisms cause swelling in spheroids but axon 
fragmentation in Wallerian degeneration. Cytoskeletal changes are common to both, so a 
loosening of cytoskeletal structure could cause disorganised cytoskeleton to accumulate 
in spheroids but to undergo rapid granular disintegration in Wallerian degeneration. 
Wallerian degeneration of injured gracile tract axons displays elements of both processes, 
possibly having an intermediate mechanism: like spheroids, these axons dilate 
considerably but, typical of Wallerian degeneration, they also rapidly lose their 
cytoskeletal proteins (George and Griffin, 1994). In traumatic brain injury, observation of 
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Wallerian degeneration and spheroids in the same transverse thin section has been 
interpreted as some axons having a more proximal spheroid that blocks axonal transport 
(Cheng and Povlishock, 1988)(Figure 5.10). In view of our findings, an additional 
explanation needs to be considered, that spheroids and Wallerian degeneration are 
alternative responses of different axons to the same lesion. Methods for real-time or long-
range longitudinal analysis of individual spheroid-containing axons are required to 
resolve this, similar to new methods already applicable in PNS axons (Beirowski et al, 
submitted). What determines whether an axon develops a spheroid or undergoes 
Wallerian degeneration? Possible explanations include the different glial and 
haematopoietic cell content of the CNS and the slower rate of axonal transport there 
(Wujek and Lasek, 1983) but injury type may also be important. Finally, since the 
discovery of the WldS mouse, Wallerian degeneration is no longer considered a passive 
wasting of distal axons but a regulated self-destruction programme (Buckmaster et al, 
1995; Raff et al, 2002). The reduction of axonal spheroid pathology by the same gene 
raises similar questions: rather than being a passive consequence of blocked axonal 
transport they could be, like Wallerian degeneration, a programmed response to axon 
damage. 
Altered ubiquitin metabolism plays important roles in neurodegenerative diseases of the 
CNS. Genetic mutations in Parkinson’s disease include an E3 ligase (Kitada et al, 1998) 
and possibly Uchl1, the human homologue of the gene mutated in gad (Leroy et al, 1998). 
Indeed there is a protective effect of WldS in a Parkinson's model as well (Sajadi et al, 
submitted). Ubiquitin positive inclusions and other evidence indicate abnormal 
ubiquitination in Alzheimer’s disease (Mori et al, 1987; van Leeuwen et al, 1998), 
polyglutamine disorders (DiFiglia et al, 1997; Cummings et al, 1999; Bence et al, 2001) 
and ALS (Tu et al, 1996; Bruijn et al, 1997). Axons and synapses are particularly 
vulnerable, as proteasome inhibitors cause specific degeneration of distal neurites (Laser 
et al, in press) and ubiquitin-related mutations alter synapse growth (DiAntonio et al, 
2001) and stability (Wilson et al, 2002). As WldS can counter a downstream effect of 
defective ubiquitin metabolism, it now becomes important to study its effects on the 
above disorders. Ironically, ubiquitin-proteasome pathway alterations also delay 
Wallerian degeneration (Mack et al, 2001; Zhai et al, 2003). 
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WldS is a unique tool to explore the relationship between axon pathology and disease 
symptoms. For example, the poor Rotarod performance of gad/WldS mice, despite 
multiple indications of reduced pathology in the gracile tract, suggests that gracile tract 
axons are not responsible for this particular behavioral deficit. Poor preservation of 
neuromuscular junctions, especially in older gad/WldS mice, is a more likely explanation. 
Why the phenotype actually worsens, however, is unclear. An interesting possibility is 
impairment of functional compensation, such as nodal or terminal sprouting, as WldS is 
known to impair axon regeneration secondarily (Brown et al, 1994). The Rotarod deficit 
in gad/WldS mice contrasts both with the lack of significant change in other tests we 
report and with the distinct improvements seen in peripheral neuropathies, motor 
neuronopathy and a Parkinson's model (Wang et al, 2002; Samsam et al, 2003; Ferri et al, 
2003; Sajadi et al, submitted). However, the behavior in the Parkinson's study was also 
not as expected from the histopathology with unexpected effects on drug-induced turning 
behavior in mice showing distal protection of their dopaminergic fibers. Thus, although 
WldS protects axons in a widening range of diseases, it is clear that we have much to learn 
about the behavioral consequences of axon protection, which need to be studied on a 
disease-specific and test-specific basis. Rapid removal of sick but “undead” cells is 
sometimes beneficial (Schulz and Nictotera, 2000) so when the regulation of Wallerian 
degeneration is sufficiently understood, it might be used to amputate sick axons 
selectively to facilitate their rapid clearance where appropriate. In other circumstances, 
however, we may wish to prolong axon survival long enough to overcome or treat a 
temporary insult and then allow the axon to return to normal. 
In summary, WldS alleviates chronic CNS axon pathology in gad mice and that formation 
of distal axonal spheroids shares a regulatory step with Wallerian degeneration and 
‘dying-back’ axon loss without spheroids. The effect of WldS on other CNS disorders 
with ubiquitination deficits or proximal axonal spheroid pathology should now be studied. 
Behavioral consequences of axon rescue are sometimes complex and must be assessed on 
a disease- and test-specific basis. Finally, it is clear that future studies need to identify 
factors protecting synapses as strongly as WldS protects axons. 
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Figure 5.1 Southern blot genotyping of gad. 1) Southern blot genotyping gad+/+, gad+/-, 
and gad-/-, genomic DNA were digested by PvuII, southern blotted and detected by 
radiolabelled gad probe (764bp).  2) Scheme of the deleted region of Uchl1 in gad mice. 
Predicted sizes of genomic level sequences of exon 6 to exon 9 of gad+/+ and gad-/- are 
shown. The restriction cutting sites for PvuII and predicted sizes of detected fragments by 
gad probe are shown.  
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Figure 5.1 Southern blot genotyping of gad-/-, gad+/-, gad+/+.  
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Figure 5.2 Slow Wallerian degeneration in WldS heterozygotes carrying homozygous gad 
alleles. (a) Western blot showing complete preservation of heavy neurofilament protein in 
distal sciatic nerve of gad homozygous plus WldS heterozygous mice five days after 
nerve transection. (b) Complete preservation of distal axon integrity in the same mice 
visualised using the YFP-H transgene. Scale bar: 100 µm. 
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Figure 5.2 
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Figure 5.3 WldS reduces spheroid body numbers in the gracile tract of gad mice. (a and c) 
Representative sections from gracile nucleus of (a) gad and (c) gad/WldS mice stained 
with H & E, showing a large reduction in the number of axonal spheroids (arrows) when 
WldS is present. (b and d) Representative sections from cervical gracile fascicle of (b) gad 
and (d) gad/WldS mice. Scale bar (a to d): 25 µm. (e and f) Quantification (mean ± SD) 
of spheroid counting data in (e) gracile nucleus and (f) cervical gracile fascicle (n=6). ** 
p < 0.01; *** p < 0.001. 
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Figure 5.3 
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Figure 5.4 WldS reduces also other measures of gracile tract pathology. (a) and (b) 
Representative gracile fascicles from cervical gracile fascile of (a) gad and (b) gad/WldS 
mice stained with Luxol Fast Blue and Nuclear Fast Red, showing the reduction in 
myelin loss when WldS is present. Scale bar (a and b): 25 µm. (c) Densitometric 
quantification (mean ± SD) of Luxol Fast Blue staining (n=5). (d) and (e) Representative 
gracile nuclei of (d) gad and (e) gad/WldS mice immunostained for GFAP, showing lower 
astrocyte activation when WldS is present. Scale bar (c and d): 25 µm. (f) Densitometric 
quantification (mean ± SD) of GFAP immunocytochemistry signal (n=5). * p < 0.05. 
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Figure 5.4 
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Figure 5.5 gad mice perform worse on Rotarod when they carry a WldS allele. Time taken 
for gad mice of increasing ages to fall from an accelerating Rotarod in the presence of 
homozygous mutant (n=9) or wild-type (n=6) alleles for WldS. Homozygous WldS causes 
deterioration to be anticipated by approximately 5.5 weeks, with significant (* p < 0.05) 
differences in performance at several individual timepoints, especially beyond 14 weeks. 
The Rotarod performance of WldS heterozygotes was also significantly worse than wild- 
type and, when combined with WldS homozygote data, gave a highly significant 
difference from wild-type (p = 0.002) at 18 weeks (data not shown). 
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Figure 5.5 
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Figure 5.6 There is no significant difference on footsplay test in gad mice with WldS 
allele or without WldS allele. Distance of hind limbs measured for gad mice of 9 weeks 
and 13 weeks to drop from a height of 15 cm to land on white paper in the presence of 
homozygous mutant (n=8) or wild-type (n=7) alleles for WldS. White blocks stand for 
gad wild type (wt) or heterozygotes (hetero); black blocks stand for gad/Wld 
homozygotes (homo); blue blocks stand for gad/Wld wild type (Wld wt).   
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Figure 5.6 
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Figure 5.7 There is no significant difference on hind limbs clasping test between gad 
mice with WldS allele (WldS homozygous or heterozygotes) or without WldS. Time taken 
for gad mice of increasing ages (from 6 week to 16 week) to clasp their hind limbs 
(Figure 2.3) within 1 minute in the presence of homozygous mutant (n=10), heterozygous 
mutant (n=14) or wild-type (n=7) alleles for WldS.  
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Figure 5.7 
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Figure 5.8 Denervation at the neuromuscular junction. At 15 weeks both (a) gad and (b) 
gad/WldS have extensive denervation, with partial occupancy of endplates by motor nerve 
terminals occurring frequently. At 9 weeks mice denervation had hardly begun in some 
mice of either genotype (c and d respectively). Scale bar: 25 µm 
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Figure 5.8 
 
 
 
 
 
 
 
 
 111
Figure 5.9 Axonal spheroids are present widely in degenerative pathology.  
a) Axonal spheroids were present in the brainstem of 7-week old npc-1-/- mice. Npc-1-/- is 
a mice model of human Niemann-Pick type C (NPC, a neurodegenerative storage 
disease), primary antibody: SMI 32 (Sternberger Monoclonals, Inc. USA), staining 
nonphospho-NF-H (Bu et al, 2002). 40 x. 
b) NF-rich spheroids were found in the anterior horn of SOD1-G93A mice at 130 days 
old, a mice model of human familial amyotrophic lateral sclerosis. Primary antibody: 
rabbit anti-NFL polyclonal anti-serum (Tu et al, 1996). Scale bar: 20 mm.      
c) Axonal spheroid swellings are present in the ventral horns of the spinal cords in Vegfd/d 
mice with ALS-like motoneuron degeneration and d) Toluidine blue staining shows a 
marked deficit or abnormal appearance of axons, endoneural fibrosis and macrophage 
infiltration (Wallerian-like degeneration) in the sciatic nerve of a Vegfd/d mice (Oosthuyse 
et al, 2001). Scale bar: 20 mm. 
e) and f) Electron microscopy of axonal spheroids from the raphe of the brain stem of 10-
month transgenic mice expressing human four-repeat tau protein. Both spheroids in e) 
and f) are surrounded by a thin myelin sheath. The axon in e) contains mostly 
intermediate-size filaments. The axon in f) contains mainly concentrically structured 
dense bodies in an electron-dense background (Probst et al, 2000). Scale bar: 2.5 mm. 
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Figure 5.9 
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Figure 5.10 Evidences show that Wallerian degeneration and axonal spheroid are related. 
a) Gracile tract axons (Lumbar cord) 46 h post-axotomy in 18-week-old rat undergo 
Wallerian degeneration with spheroid-like dimensions quite unlike Wallerian 
degeneration in the PNS. Scale bar, 0.1 mm. 
b) In traumatic brain injury, Wallerian degeneration and spheroids in the same 
transverse thin section has been observed. At 14 days posttrauma, electron 
microscopy demonstrates a reactive swelling with a focally disrupted axolemma, 
degenerating mitochondria and electron-dense bodies. Wallerian change (arrows) 
of segments of injured axons distal to the reactive swelling is reflected in the 
appearance of electron-dense and collapsed axonal profiles. 5600 x.    
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Figure 5.10 
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Figure 5.11 WldS delays a central step of axonal pathology that lies after the convergence 
point of multiple degenerative stimuli but upstream of the divergence of several 
pathological manifestations. 
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Figure 5.11 
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6.1 Introduction 
Axons and their synapses distal to an injury undergo rapid Wallerian degeneration, but 
axons in the C57BL/WldS mouse are protected in such processes for 3 weeks after 
transection (Lunn et al, 1989). The degenerative and protective mechanisms are unknown. 
However the protective gene was identified in our lab (Mack et al, 2001), and encodes an 
N-terminal fragment of ubiquitination factor E4B (Ube4b) fused to nicotinamide 
mononucleotide adenylytransferase (Nmnat). The yeast homolog of Ube4b is required to 
multi-ubiquitinate some substrate proteins (Koegl et al, 1999) and a direct link between 
ubiquitination and axon degeneration comes from the Uch-l1 mutation in gracile axonal 
dystrophy (Saigoh et al, 1999). However, the WldS protein contains only 70 of 1,173 
amino acids from Ube4b, and these are absent from the yeast homolog. They are 
therefore unlikely to confer multi-ubiquitination activity but may have a related role. 
However, the protective mechanism could still work through Ube4b sequences, possibly 
due to sequestering of ubiquitination factors by protein-protein interactions. Nmnat is a 
nuclear protein and known to catalyze the reaction NMN + ATP ® NAD+ + Ppi (Magni 
et al, 1999), a reaction generally assumed not to be at equilibrium because of the 
constitutive action of pyrophosphatases. Chimeric protein WldS contains full-length 
sequence of Nmnat, however, whether it has Nmnat enzyme activity was unknown. 
Several projects to characterize WldS protein are ongoing in the lab, such as studying the 
localization of WldS protein, finding the binding partners of N-terminal fragment of WldS, 
knocking out Ube4b, the parent gene of N-terminal 70 amino acids of WldS.  All of these 
projects use the N70 antibody that I generated (see below).  In addition, I describe how I 
expressed WldS fusion protein for analysis of intrinsic Nmnat enzyme activity by a 
collaborating group and my generation and analysis of transgenic N70 with nucleus 
localization signal (NLS) or nucleus export signal (NES) etc.  
 
6.2 Results 
6.2.1 Identifying the WldS gene and its initial characterization 
Prior to the beginning of this work, a transgenic mouse line had been made (E34) to test 
the hypothesis that the chimeric gene was the WldS gene. This formal proof was 
necessary because there is only one mutant allele for WldS and other genes are also 
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altered by the triplication. Thus, the correlation between inheritance of chimeric gene and 
the WldS phenotype is not alone proof of causality. E34 was made using a construct with 
Nmnat plus 54 nucleotides at the junction and 33 nucleotides of truncated N-terminal 210 
nucleotides of Ube4b from a β-actin promoter.  It was known not to show the WldS 
phenotype (Figure 6.1a), but at the beginning of the work, it was not known whether this 
line expressed protein. Two antibodies had been made using synthetic peptides (amino 
acids shown in bold in Figure 1.4, were used to make peptides for generation of 
polyclonal antisera), but had not been tested on Western blots, and it was important to 
know whether line E34 did express the protein. If it did not, we could not have made any 
conclusion about the identity of the gene; if it did, it would have suggested that this 
construct did not contain a fully-functioning WldS gene. In joint work by myself and Dr. 
Till Mack, line E34 was found to express the unique protein but, surprisingly, it was 6-7 
kDa smaller than WldS-specific protein showed in brain homogenates in C57BL/WldS 
mouse. To sort out the possible explanation of the difference between transgenic and 
WldS, Dr. Michael Coleman re-examined the sequence, and found out there were 177 
nucleotides (59 amino acids) missing at the N-terminus. Thus new transgenic lines were 
made which included the missing N-terminus (full sequence of WldS gene shown in 
Figure 1.4 and the transgenic construct shown in Figure 6.1a). 
While generation of the new transgenics was in progress, I generated a new antiserum.  
This was necessary because the anti-peptide antibodies recognised the WldS protein only 
weakly, along with many non-specific background bands.  Recombinant N70 protein, 
whose sequence is shared between WldS and wild-type Ube4b (ubiquitination factor E4B) 
was made to raise rabbit polyclonal antibody using the services of Eurogentec 
(Eurogentec, Belgium). N-terminal 210 nucleotides of chimeric WldS (sequence see 
Figure 1.4) was amplified by PCR, cloned into NheI / XhoI double-digested pET-28b (+) 
vector (Figure 2.2) and expressed in BL21 (DE3) E.coli strain (data not shown). The 
Nickel-chelating resin was used to purify recombinant N70 protein with polyhistidine (6 
x His) (ProBondTM, Invitrogen) and purified recombinant protein was frozen (-20°C) and 
shipped to Eurogentec for raising polyclonal antisera in two rabbits.  
The polyclonal antibodies against recombinant N70 from both rabbits did recognize WldS 
protein and Ube4b (Figure 6.3). The further affinity purification of antibody was done by 
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Postdoctoral fellow Dr. Till Mack in the lab (2.1.7). The purified antibody was used for 
the WldS localization study in isocortex and motor neurons (done by Bogdan Beirowski), 
showing the predominant nuclear localization of WldS protein (Figure 6.2). Dr. Till Mack 
also used it to show that Ube4b expression is unaltered in WldS mice and to study WldS 
expression in WldS mice at different ages, showing age-independent protection of axons 
(Gillingwater et al, 2002) (Figure 6.3).  Dr. Heike Laser used it to study binding 
interactions between N70 and other proteins.  Finally, I describe below how I used it 
myself in the transgenic N70 project (see section 6.2.2). 
Since the WldS gene was confirmed by at least 3 lines of transgenic mice (Mack et al, 
2001), and it encodes an N-terminal fragment of ubiquitination factor E4B (Ube4b) fused 
to nicotinamide mononucleotide adenylytransferase (Nmnat), the questions were 
addressed: which part of the gene does the job to delay Wallerian degeneration in axons, 
or does the protective effect needs both parts, and what could the mechanism be? Part of 
my contribution to this was to make recombinant WldS protein for Nmnat enzyme 
activity analysis, since nucleotides 282-1140 of WldS spans the entire Nmnat open 
reading frame. Full-length chimeric gene (sequence see Figure 1.4) was amplified by 
PCR, cloned into NheI / XhoI double-digested pET-28b (+) vector (Figure 2.2) and 
expressed in BL21 (DE3) E.coli strain (data not shown). The Nickel-chelating resin was 
used to purify recombinant chimeric protein with polyhistidine (6 x His) (ProBondTM, 
Invitrogen) and purified recombinant protein was frozen (-20°C) and shipped to our 
collaborator’s lab in Italy (Professor Giulio Magni) for Nmnat enzyme activity assay. The 
purified protein was found to have Nmnat enzyme activity, but a meaningful specific 
activity could not be calculated since protein had partly degraded during shipping.  
However, the observed specific activity in a WldS bacterial lysate (0.96 U/ mg) was 
comparable with that of a bacterial lysate containing recombinant human Nmnat (1.74 U / 
mg) (Figure 6.4) (Emanuelli et al, 2001), suggesting that the degree of activity in WldS 
protein is considerable. To determine whether there is a corresponding increase in Nmnat 
activity in WldS mice, our collaborators studied Nmnat activity in brain homogenates and 
found a fourfold increase in WldS brain compared to C57BL/6J (p<0.05, Figure 6.4). The 
total content of NAD+, however, was not significantly altered (p=0.2; Figure 6.4). 
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Therefore, the Wld protein confers an increase in Nmnat activity without altering the 
steady-state level of NAD+.     
6.2.2 Transgenic N70 plus NLS or NES does not show WldS phenotype 
The failure of WldS protein to alter resting NAD+ levels, together with the absence of a 
WldS phenotype in E34 mice, suggested that the N-terminal region (N70) of the WldS 
protein is necessary for the phenotype. I then made transgenic mice with N70 plus 
Nucleus Localization Signal (NLS) or Nucleus Export Signal (NES).  The aim was to 
clarify two question 1) whether N70 itself is enough to delay Wallerian degeneration and 
2) whether the nucleus localization is essential for the phenotype since WldS protein is 
predominantly expressed in nucleus (Mack et al, 2001) (Figure 6.2).  
I cloned N70-NLS or N70-NES with flag tag downstream of b-actin promoter in BamHI-
digested pHbApr-1 (Figure 2.1, Figure 6.1b and Figure 6.1c) and confirmed their 
orientation by sequencing. To check whether Nucleus Localization Signal (NLS) and 
Nucleus Export Signal (NES) do confer the localization of recombinant protein in 
nucleus (N70-NLS) or cytoplasm (N70-NES), I transfected transgenic construct pHbApr-
1-N70-NLS or pHbApr-1-N70-NES into COS-7 cells, and it showed that pHbApr-1-
N70-NLS was expressed in nucleus, and pHbApr-1-N70-NES was expressed in 
cytoplasm as expected by anti-flag-tag monoclonal antibody (see above and Figure 6.5).  
To further characterize the role of N70-NLS and N70-NES, transgenic mice expressing 
the N70-NLS or N70-NES from a b-actin promoter were generated. The N70-NLS and 
N70-NES fragments with b-actin promoter was excised from the plasmid, purified using 
Qiaquick extraction kit and then shipped for injection into C57BL/CBA F1 mouse 
pronuclei using the service of Professor George Kollias (Alexander Fleming Research 
Center, Vari, Greece).  I then performed DNA extraction and genotype analysis to 
identify founders and control further breeding. One transgenic line (line 311) was 
confirmed positive by Southern blotting for N70-NLS expression with multi-copy 
integration. Three lines of transgenic N70-NES (line 213, 215, and 219) were confirmed 
positive by a strong PCR signal and chosen for further analysis.  
To test whether N70-NLS or N70-NES confer the WldS phenotype, the structural 
preservation of axons several days after axotomy were examined either by western 
blotting for the preservation of heavy neurofilament protein or by visualizing YFP signal 
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(Feng et al, 2000) for axonal integrity. Following unilateral sciatic nerve transection in 
~7, 8 or 12 week old mice, a nerve segment 2-4 mm distal to the lesion after 53 h, 56h or 
3 days was taken for western blotting, and tibial nerve was taken for YFP signal 
visualization. None of transgenic N70-NLS or N70-NES homozygotes or heterozygotes 
show preservation of axons either in 3 days lesion, 56 hours or 53 hours low stringency 
lesion (Table 6.1). However no N70-NLS or N70-NES protein expression was detectable 
in western blotting (data not shown), thus to conclude whether N70 itself could alter 
Wallerian degeneration may require further transgenic lines to be generated. 
 
6.3 Discussion 
We showed that polyclonal antibodies against recombinant N70 are suitable for western 
blotting and immunocytochemistry studies to examine WldS protein expression level and 
localization (Figure 6.2 and 6.3). Such polyclonal anti-N70 antibodies could also be used 
for other application, such as confirming WldS expression in substantia nigra 
dopaminergic neurons of WldS mice with 6-hydroxydopamine (6-OHDA) lesion, a mouse 
model of Parkinson disease (Sajadi et al, submitted). It could be applied for studying the 
potential binding partner of N70 by immunoprecipitation as well, and other studies which 
should lead towards the mechanism of axon protection by WldS. 
The predominant WldS protein expression in nucleus and its non-homogeneous 
intranuclear distribution suggest that the protective mechanism could involve 
sequestering of ubiquitination factors by protein-protein interactions. Ubiquitination 
could thus be altered within the nucleus, altering transcription factor stability or RNA 
processing, leading to an axon effect mediated by unknown proteins. Alternatively, 
ubiquitination in cytoplasm or axon might be altered by sequestration of ubiquitination 
factors normally located there.  Although there was a fourfold increase in WldS brain 
homogenates compared to C57BL/6J, the total content of NAD+ was not significantly 
altered. It thus suggests the putative additional NAD+ is metabolized in WldS. The 
product of a compensatory reaction could itself be involved in axon protection. For 
example, mild activation of PARP without NAD+ depletion can be neuroprotective 
(Nagayama et al, 2000); synthesis of the signaling molecule cyclic ADP ribose from 
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NAD+ regulates calcium release from intracellular stores, potentially influencing calcium 
activated proteases in Wallerian degeneration (Di Lisa et al, 2001).      
We did not see WldS phenotype in transgenic N70-NLS or N70-NES, several reasons 
could account for this: firstly, we did not detect any N70-NLS or N70-NES protein 
expression by western blotting although we detected convincingly transgene integration 
into the chromosome by Southern blotting. If there is no N70-NLS or N70-NES 
expression in transgenic mice at all, we could not make any conclusion to exclude N70’s 
possible role in delaying Wallerian degeneration. Such doubt may be resolved in future 
studies by making additional transgenic mice. Secondly, it could be that protein 
expression level (N70-NLS or N70-NES) is not high enough to confer any WldS 
phenotype, since WldS phenotype is highly dose-dependent (Mack et al, 2001). Thirdly, it 
could be N70 itself could not complete the role in delaying Wallerian degeneration and it 
does need other parts of the WldS protein, such as Nmnat sequence or the 18 amino acid 
joining region. Ongoing experiments by Dr. Heike Laser to look for the binding partners 
of N70 by yeast two-hybrid and biochemical analysis might also indicate the role of N70. 
Alternatively, knock out of N70 parent gene Ubiquitination factor E4B (Ube4b) could 
also give us information as to whether WldS works with Ube4b on delaying Wallerian 
degeneration, or whether defective in Ube4b partially mimics the WldS phenotype and 
thus its downstream effect could possibly play a role on the protective mechanism. Such 
experiments using a gene-trap ES cell clone are in progress (Dr. Michael Coleman and Dr. 
Neil Smyth), although early indications are that there may be splicing across the 
interruption in Ube4b.  Alternatively, the mechanism of WldS could be studied by testing 
the effect of other mutations (e.g., knock-outs or spontaneous mutants with known altered 
gene) to find one with a similar effect on axon. A connection between WldS and such a 
mutation with known defective pathway would shed light on the WldS mechanism.  
 
 
 
 
 
 124
Figure 6.1a the transgenic construct of Ube4b/Nmnat. The chimeric cDNA (consisting of 
the N-terminal 210 coding nucleotides of Ube4b, the entire 855 coding nucleotides of 
Nmnat, and 54 nucleotides formed at the junction) was expressed with non-coding exon 1 
of β-actin under the control of a human β-actin promoter and terminated with the SV40 
polyadenylation signal. 
 
 
 
 
Figure 6.1b the transgenic construct of N70 plus NLS. N-terminal 210 coding nucleotides 
of chimeric WldS with 3 x NLS of the SV40 large T antigen and Flag tag was expressed 
with non-coding exon 1 of b-actin under the control of a human b-actin promoter and 
terminated with the SV40 polyadenylation signal. 
 
 
Figure 6.1c the transgenic construct of N70 plus NES. N-terminal 210 coding nucleotides 
of chimeric WldS with NES and Flag tag was expressed with non-coding exon 1 of b-
actin under the control of a human b-actin promoter and terminated with the SV40 
polyadenylation signal. 
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Figure 6.1a the transgenic construct of chimeric gene.  
 
  
 
 
 
 
Figure 6.1b the transgenic construct of N70 plus NLS. 
  
  
 
 
 
 
 
Figure 6.1c the transgenic construct of N70 plus NES. 
 
 
 
 
  
 
 
54 nucleotides at 
the junction 
Hind III ATG 
STOP 
BamHI 
cDNA 
Promoter 
N70 NES 
Non-coding exon 1 
of b-actin 
SV40 Poly A 
54 nucleotides at 
the junction 
Hind III ATG 
STOP 
BamHI 
cDNA 
Promoter 
N70 3 x NLS 
Non-coding exon 1 
of b-actin 
SV40 Poly A 
Flag tag 
54 nucleotides at 
the junction 
Hind III ATG STOP 
BamHI 
cDNA 
Promoter 
N70 Nmnat 
Non-coding exon 1 
of b-actin 
SV40 Poly A 
Flag tag 
 126
Figure 6.2 The intracellular location of the WldS protein. a) presence of the WldS protein 
in neuron nuclei of isocortex and b) its absence from C57BL/6J control tissue. Red, anti-
N70 antibody, which detects WldS and Ube4b. Green, anti-MAP2 antibody markedly 
outlining neuronal cell bodies. (c-e) Motor neurons in thoracic spinal cord of both WldS 
(c) and transgenic line 4836 (d) (see details in section 1.4) expressed the WldS protein 
(red) in their nuclei, whereas those of C57BL/6J (e) did not. Cytoplasmic signals may be 
Ube4b or low level WldS protein. Counter stain, neurofilament (green) (Mack et al, 2001).   
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Figure 6.2 
Isocortex 
 
 
 
 
 
 
Motor neurons in thoracic spinal cord  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c d 
e 
a b 
 128
Figure 6.3 Western blotting shows Ube4b, WldS and β-tubulin (loading control) 
expression in WldS mice of different ages (2 months, 4 months, 7 months and 12 months) 
compared to a 6J mouse control (Gillingwater et al, 2002).  
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Figure 6.3 
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Figure 6.4 a) Commasie-blue protein gel show the chimeric gene lysate (recombinant 
chimeric protein expressed in E.coli) and the control lysate (Ecoli without recombinants 
chimeric protein expression), the observed specific activity for Nmnat of chimeric protein 
bacterial lysate is 0.96 U/mg, which is comparable with that of a bacterial lysate 
containing recombinant human NMNAT (1.74 U/mg) (Emanuelli et al, 2001).  
b) Increased Nmnat activity and unaltered NAD+ content in WldS brain. Bar charts show 
Nmnat specific activity and NAD+ content in homogenates of fresh brain from 
homozygous WldS and C57BL/6J mice. Means and standard error are shown (n=3) (Mack 
et al, 2001). 
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Figure 6.4 
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Figure 6.5 Transfection of COS-7 cell with pHbApr-1-N70-NLS or pHbApr-1-N70-NES, 
shows the predominant nucleus expression with N70-NLS (a), and cytoplasm expression 
with N70-NES (b). Red, anti-flag-tag M2 monoclonal antibody (Sigma, Germany); Blue, 
DAPI nucleus staining.  
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Figure 6.5 
a)  
                                         
 
 
 
 
b) 
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Figure 6.6 Transgenic N70-NLS and N70-NES do not show WldS phenotype. 
a) Western blot showing the extent of 200-kD neurofilament protein degradation in 
distal sciatic nerve of N70-NLS or N70-NES heterozygotes/homozygote 56 hours 
after nerve transection. Complete preservation of NF-200 in uncut contralateral 
nerve was shown as well. 
b) Fragmentation of distal axon integrity in N70-NLS or N70-NES homozygotes 53 
hours after nerve transection using the YFP-H transgene. Scale bar: 100 mm. 
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Figure 6.6 
a)  
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Table 6.1 Results of preservation of axons in transgenic N70-NLS or N70-NES mice by 
western blot (for preservation of neurofilaments) or visualizing YFP signal (for axonal 
integrity). Hetero = heterozygote; Homo = homozygote; WB = western blot. 
a) Transgenic N70-NLS 
Mice No. Genotype Lesion time Result Age 
38m2 NLS hetero + 
YFP 
3 days No preservation 
in WB and YFP 
~7 week old 
38m4 NLS hetero + 
YFP 
3 days No preservation 
in WB and YFP 
~7 week old 
39m3 NLS hetero 3 days No preservation 
in WB 
~7 week old 
37f2 NLS hetero + 
YFP 
56 h No preservation 
in WB and YFP 
~8 week old 
37f5 NLS hetero + 
YFP 
56 h No preservation 
in WB and YFP 
~8 week old 
37f6 NLS hetero + 
YFP 
56 h No preservation 
in WB and YFP 
~8 week old 
37m2 NLS hetero 
+YFP 
56 h No preservation 
in WB and YFP 
~8 week old 
36f3 NLS homo + 
YFP 
56 h No preservation 
in WB and YFP 
~8 week old 
36m4 NLS homo + 
YFP 
56 h No preservation 
in WB and YFP 
~8 week old 
34m3 NLS homo + 
YFP 
53 h No preservation 
in WB and YFP 
~12 week old 
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b) Transgenic N70-NES 
Mice No. Genotype Lesion time Result Age 
34 f3 NES hetero 3 days No preservation 
in WB 
~8 week? 
34f4 NES hetero + 
YFP 
3 days No preservation 
in WB and YFP 
~8 week? 
42m1 NES hetero 3 days No preservation 
in WB 
~7 week old 
42m2  NES hetero 3 days No preservation 
in WB 
~7 week old 
41f4 NES hetero 3 days No preservation 
in WB 
~7 week old 
42f5 NES hetero 3 days No preservation 
in WB 
~7 week old 
47f2 NES hetero 56 h No preservation 
in WB 
~8 week old 
47m3 NES hetero 56 h No preservation 
in WB 
~8 week old 
47m4 NES homo 56 h No preservation 
in WB 
~8 week old 
39f3 NES homo + 
YFP 
53 h No preservation 
in WB and YFP 
~12 week old 
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Summary 
The slow Wallerian degeneration mouse, C57BL/WldS, carries a dominant mutation 
which delays Wallerian degeneration in the distal stump of an injured axons for several 
weeks in both central and peripheral nervous system (CNS and PNS). A highly unusual 
85 kb tandem triplication was previously identified in the WldS mouse and during the 
period of my PhD work was shown to be the causative mutation, acting through a 
Ube4b/Nmnat chimeric gene contained within it.  
The aims of project described in this thesis were 1) to develop a suitable method to track 
the inheritance of the 85 kb tandem triplication WldS allele; 2) to investigate the 
instability of 85 kb triplication at the chromosomal level; 3) to explore whether WldS 
could alleviate or rescue axon loss in PNS and CNS neurodegenerative disease by 
crossing WldS with mouse models of neurological disorders; 4) to characterize WldS 
protein and 5) to investigate the possible mechanism involving in delaying Wallerian 
degeneration. 
Three genotyping methods for WldS were developed, namely PCR, Southern blotting and 
pulsed field gel electrophoresis (PFGE) (Chapter 3). The relative merits of these three 
methods for genotyping of WldS are discussed: PFGE is the only qualitative method to 
distinguish homozygotes from heterozygotes, but usually needs to be done post-mortem; 
PCR is a quick assay, however it is difficult to distinguish homozygotes from 
heterozygotes, or wild-type from false negative; Southern blotting could resolve the false 
negative problem in PCR with a constant wild-type band as an internal control, but could 
only distinguish homozygotes from heterozygotes partially by the relative strength of 
WldS-specific band and the constant band.  
The PFGE method was used to look for any possible instability of the 85 kb tandem 
triplication in WldS at the chromosome level (Chapter 4). In total 180 chromosomes of 
WldS from three divergent breeding colonies at different ages have been examined and 
all found to carry the triplication. Thus, the triplication mutation is stable during both 
mitosis and meiosis. Such a study almost rules out instability as a source of phenotypic 
variation.  It is essential to know this for accurate interpretation of studies the effect of 
WldS on neurodegenerative phenotypes (see Chapter 5). 
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At the outset of this work, the effect of WldS on axon degeneration in disease, as opposed 
to injury, was completely unknown.  I collaborated with the group of Rudolf Martini 
(University of Würzburg) in a study showing that WldS protects axons in a myelin-related 
peripheral neuropathy (the P0-/- mouse)(Chapter 3).  Simultaneously, work in another 
collaborating group revealed a similar protective effect in progressive motor 
neuronopathy (pmn). To investigate whether WldS has effect on axonal loss in CNS 
neurological disorders, I crossed WldS with gad (gracile axonal dystrophy) mice (Chapter 
5), a simple genetic mouse model (with a defect in Uchl1, ubiquitin carboxy-terminal 
hydrolase l1) of CNS neurodegenerative disease with a defect in ubiquitin system and 
axonal spheroid pathology in CNS. WldS significantly reduced axonal spheroid numbers 
and secondary pathology (myelin loss and astrocyte activation). However, neuromuscular 
synapse pathology still developed with age, leading probably to the complex behavioral 
changes observed. The observations that WldS can alleviate axonal spheroid pathology in 
gad mice in our study and also delay axon loss in PNS disorders with dying-back axon 
degeneration in our collaborators' studies, suggest that formation of distal axonal 
spheroids shares a regulatory step with Wallerian degeneration and ‘dying-back’ axon 
loss without spheroids, and that WldS delays a central step of such axon pathology. 
Ube4b/Nmnat (WldS) is known to delay Wallerian degeneration, however the protective 
mechanism is unknown. I also contributed to studies to characterize WldS and its role in 
delaying Wallerian degeneration.  Firstly, I generated recombinant protein and polyclonal 
antiserum that were used to show that WldS protein is predominantly nuclear.  Secondly, 
I generated transgenic mice carrying the N-terminal 70 amino acid (N70) of WldS fused 
with nuclear localization signal (NLS) or nuclear export signal (NES) to test whether the 
N70 was sufficient for the WldS phenotype and in which intracellular compartment it has 
to be located. The phenotype was analyzed by examining the preservation of 
neurofilament protein in lesioned nerves by western blotting or axonal integrity using a 
YFP marker protein. Transgenic N70-NLS or N70-NES heterozygotes / homozygotes did 
not show WldS phenotype, however there was not detectable N70-NLS or N70-NES 
protein expression level by western blotting. 
In conclusion, pulsed field gel electrophoresis (PFGE) is the only qualitative method to 
distinguish WldS homozygotes from heterozygotes comparing to the alternatives of PCR 
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and Southern blotting. The WldS triplication is stable under normal conditions and is the 
predominant, and possibly exclusive, allele in the current WldS breeding colonies. WldS 
alleviates chromic PNS and CNS axon pathology in gad mice. Formation of distal axonal 
spheroids shares a regulatory step with Wallerian degeneration and ‘dying-back’ axon 
loss without spheroids. The N70-NLS or N70-NES experiments were inconclusive with 
the existing transgenic lines but WldS was shown to be a predominantly nuclear protein 
using the antiserum that I generated.  
   
 
Zusammenfassung 
Die C57BL/WldS (langsame Waller’sche Degeneration) Maus, besitzt eine dominante Mutation, welche die Waller’sche 
Degeneration am distalen Ende eines verletzten Axons sowohl im zentralen (ZNS), als auch im peripheren Nervensystem 
(PNS) über mehrere Wochen hinauszögert.  Eine äußerst ungewöhnliche 85 kb Tandem Triplikation wurde vorher in der WldS 
Maus identifiziert.  Während meiner Dissertationsarbeit konnte  gezeigt werden, daß diese Mutation über ein darin enthaltenes 
Ube4b/Nmnat chimeres Gen agiert.  
Die Ziele des Projektes dieser Dissertation sind: 1) Die Entwicklung einer geeigneten Methode zur Verfolgung der Herkunft 
des 85 kb Tandem Triplikation WldS Allels, 2) die Untersuchung der Stabilität der 85 kb Triplikation auf chromosomaler 
Ebene; 3) die Erkundung ob WldS den Axonenverlust bei neurodegenerativen Krankheiten  im PNS und ZNS durch Kreuzung 
mit deren Mausmodellen abmildern oder verhindern kann;  4) die Charakterisierung des WldS Proteins und 5) die 
Untersuchung von möglichen Mechanismen, welche die Waller’sche Degeneration verzögern. 
Drei Methoden zur Genotypenbestimmung von WldS wurden entwickelt: PCR, Southern Blotting und Pulsed-Field Gel 
Electrophorese (PFGE) (Kapitel 3).  Die relativen Vorteile dieser drei Methoden zur Genotypisierung von WldS werden im 
folgenden diskutiert:  PFGE ist die einzige qualitative Methode um Homozygoten von Heterozygoten zu unterscheiden, muß 
aber post-mortem durchgeführt werden;  PCR ist eine rapide Methode, bei der es aber schwierig ist, Homozygoten von 
Heterozygoten, oder Wildtypen von Falsch-Negativen zu unterscheiden;  Southern Blotting würde das Problem der Falsch-
Negativen im PCR mithilfe einer konstanten Wildtyp-Bande als Standard lösen, erlaubt aber die Unterscheidung von 
Homozygoten von Heterozygoten nur über einen Vergleich der relativen Bandintensitäten der WldS mit der Standardbande.    
Die PFGE Methode wurde verwendet, um eventuelle Instabilitaeten der 85 kb Triplikation in WldS auf chromosomaler Ebene 
zu untersuchen (Kapitel 4).  Es wurden insgesamt 180 Chromosomen von WldS aus drei divergenten Kolonien und bei 
verschiedenen Altersabschnitten untersucht, und alle enthielten die Triplikation.  Dies zeigt die Stabilität der Triplikation 
während der Mitose als auch der Meiose.  Diese Untersuchung diente vor allem dazu, Chromosomeninstabilität als Quelle von 
phänotypischer Variation auszuschließen.  Für die genaue Auswertung der Untersuchungen der Wirkung von WldS auf 
neurodegenerative Phänotypen (siehe Kapitel 5) war diese Feststellung essentiell. 
Im Gegensatz zu den Effekten von WldS auf Läsionen waren zu Beginn dieser Arbeit die Effekte von WldS auf axonal 
degenerative Krankheiten noch völlig unbekannt.  In Kollaboration mit der Gruppe von Rudolf Martini (Universität Würzburg) 
arbeitete ich an einer Studie, die zeigte, daß WldS Axone in einer Maus mit einer Myelin Neuropathie im PNS (P0-/- Maus) 
schützt (Kapitel 3).  Gleichzeitig konnte in Zusammenarbeit mit einer anderen Gruppe ein ähnlicher Schutzeffekt bei der 
Progressiven Motorneuropathie (pmn) gezeigt werden.  Um zu untersuchen, ob WldS eine Wirkung auf den Axonenverlust in 
neurologischen Krankheiten des ZNS hat, kreutzte ich WldS mit gad (gracile axonal dystrophy) Mäusen (Kapitel 5).  gad ist 
ein einfaches genetisches Mausmodell (Defekt in Uchl1, der Ubiquitin carboxyterminalen Hydrolase l1) einer zentral 
neurodegenerativen Krankheit mit einem Defekt im Ubiquitin System und axonaler Spheriod Pathologie.  WldS konnte im 
signifikanten Maße die Anzahl der Spheroide und sekundäre pathologische Symptome wie Myelinverlust und 
Astrozytenaktivation reduzieren.  Pathologische Symptome der Muskelsynapsen entwickelte sich dennoch mit wachsendem 
Alter, wodurch vermutlich die Entwicklung komplexer Verhaltensänderungen herbeigeführt wurde.  Sowohl die 
Beobachtungen in unseren Studien, daß WldS die Pathologie der axonalen Spheroide in gad Mäusen abmildert, als auch die 
Beobachtungen der kollaborierenden Gruppe, daß WldS die Axonverluste in PNS Krankheiten mit Rückdegeneration  
verzögert , läßt vermuten, daß  die Formation eines Spheroids im distalen Axon bei einem regulatorischen Schritt stattfindet, 
und zwar sowohl bei der Wallerdegeneration und als auch bei rückdegenerierenden Axonverlusten ohne Spheroidformation.  
WldS verzögert daher einen zentralen Schritt in der Pathologie von Axonen. 
Es ist bekannt, daß Ube4b/Nmnat (WldS) die Wallerdegeneration verzögert, jedoch ist der protektive Mechanismus unbekannt.  
Ich habe daher Untersuchungen durchgeführt, die zur Charakterisierung von WldS führten, und dessen Rolle in der 
Verzögerung der Waller Degeneration darstellten.  Zunächst generierte ich ein rekombinantes Protein und ein polyklonales 
Antiserum, mit deren Hilfe es ist gezeigt worden, daß das WldS Protein sich überwiegend im Nukleus befindet.  Zweitens 
produzierte ich eine transgene Maus, welche die N-terminalen 70 Aminosäuren (N70) von WldS in Fusion mit einem 
Nuklearen Lokalisations Signal (NLS) bzw. Nuclear Export Signal (NES) enthielt.  Diese dienten dazu zu testen, ob N70 
allein genügte, um den WldS Phänotyp hervorzurufen, und in welchem Zellkompartiment das Protein lokalisiert war.  Der 
Phänotyp wurde anhand der  Erhaltung von Neurofilament Proteinen in den verletzten Nerven untersucht.  Die Experimente 
liefen über Western Blot bzw. über Untersuchungen der Axonenintergrität unter Verwendung eines YFP Marker Proteins.  
Transgene N70-NLS oder N70-NES Heterozygoen bzw. Homozygoten  zeigten keinen WldS Phänotyp, wobei aber auch keine 
N70-NLS oder N70-NES Proteine im Western Blot detektiert wurden. 
Im Vergleich zu den Methoden PCR und Southern Blotting war PFGE letztendlich die einzige qualitative Methode um WldS 
Homozygoten von Heterozygoten zu unterscheiden. Die WldS Triplikation ist unter Normalbedingungen stabil und ist das 
prädominierende und möglicherweise einzige Allel in den gegenwärtigen WldS Züchtungen.  WldS  mildert chronische 
pathologische Sympome in PNS und ZNS Axonen von gad Mäusen.  Die Formation eines distalen axonalen Spheroids 
repräsentiert einen Regulationsschritt bei der Wallerdegeneration und bei rückwärtigen Axonenverlusten ohne Spheroide.  Die 
N70-NLS und N70-NES Experimente waren bei den vorhandenen transgenen Kolonien nicht eindeutig, aber unter dem von 
mir hergestellten Antiserum konnte gezeigt werden, daß WldS ein vorüberwiegend nuklear lokalisiertes Protein ist. 
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